Methods and compositions for treating feline aging
A combination of mTOR inhibitors, mirtazapine, acarbose or metformin, glycine, and N-acetyl-L-cysteine treats age-related diseases in cats, reversing sarcopenia and improving geriatric outcomes by enhancing muscle thickness and weight gain.
Patent Information
- Application Number
- PCT/US2026/026642
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
There are currently no therapeutics available to treat age-related diseases such as kidney failure, arthritis, and sarcopenia in companion cats, which are common in geriatric felines.
A composition comprising at least one mTOR inhibitor, mirtazapine, acarbose or metformin, glycine, and N-acetyl-L-cysteine is administered to treat geriatric syndromes and increase longevity in felines, formulated as oral formulations like pills, tablets, or capsules.
The composition effectively reverses symptoms of aging, including sarcopenia and weight loss, and improves geriatric outcomes by increasing muscle thickness and weight gain in elderly cats, while being well-tolerated and safe over 12 weeks.
Smart Images

Figure US2026026642_12112026_PF_FP_ABST
Abstract
Description
Attorney Docket No: 105619-000001WOPTMETHODS AND COMPOSITIONS FOR TREATING FELINE AGINGCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit under 35 U.S.C. § 119 of U.S. Provisional Application No. 63 / 802,051 filed May 8, 2025, the contents of which are incorporated herein by reference in their entirety.TECHNICAL FIELD
[0002] The technology described herein relates to treatment of conditions associated with aging, e.g., in felines.BACKGROUND
[0003] Age-related diseases (kidney failure, arthritis, sarcopenia) ultimately affect the companion cats of 74M Americans. There are currently no therapeutics for feline aging.SUMMARY
[0004] The inventors have identified treatments that can reverse symptoms of aging including sarcopenia, weight loss, and multiple biomarkers of aging and poor geriatric outcomes.
[0005] In one aspect of any of the embodiments, described herein is a composition or combination comprising at least two of:a) at least one mTOR inhibitor;b) mirtazapine;c) at least one of acarbose and metformin;d) glycine; ande) N-acetyl-L-cysteine.In some embodiments of any of the aspects, the composition or combination comprises at least two of:a) at least one mTOR inhibitor;b) mirtazapine; andc) at least one of acarbose and metformin.In some embodiments of any of the aspects, the composition or combination comprises at least three of:a) at least one mTOR inhibitor;b) mirtazapine;c) at least one of acarbose and metformin;d) glycine; ande) N-acetyl-L-cysteine.In some embodiments of any of the aspects, the composition or combination comprises each of:14928-7411-2416 2Attorney Docket No: 105619-000001WOPTa) at least one mTOR inhibitor;b) mirtazapine; andc) at least one of acarbose and metformin.In some embodiments of any of the aspects, the composition or combination comprises at least four of:a) at least one mTOR inhibitor;b) mirtazapine;c) at least one of acarbose and metformin;d) glycine; ande) N-acetyl-L-cysteine.In some embodiments of any of the aspects, the composition or combination comprises each of:a) at least one mTOR inhibitor;b) mirtazapine;c) at least one of acarbose and metformin;d) glycine; ande) N-acetyl-L-cysteine.
[0006] In some embodiments of any of the aspects, the at least one mTOR inhibitor is rapamycin. In some embodiments of any of the aspects, the composition or combination comprises acarbose. In some embodiments of any of the aspects, the composition or combination comprises metformin. In some embodiments of any of the aspects, the composition or combination comprises metformin and acarbose.
[0007] In some embodiments of any of the aspects, the composition or combination comprises the at least one mTOR inhibitor is at a dosage of 0.1 mg to 1 mg. In some embodiments of any of the aspects, the composition or combination comprises the rapamycin is at a dosage of 0.1 mg to 1 mg. In some embodiments of any of the aspects, the composition or combination comprises the mirtazapine is at a dosage of 1 mg to 3 mg. In some embodiments of any of the aspects, the composition or combination comprises the acarbose is at a dosage of 5 mg to 20 mg. In some embodiments of any of the aspects, the composition or combination comprises the metformin is at a dosage of 1 mg to 20 mg. In some embodiments of any of the aspects, the composition or combination comprises the glycine is at a dosage of 100 mg to 400 mg. In some embodiments of any of the aspects, the composition or combination comprises the N-acetyl-L-cysteine is at a dosage of 100 mg to 400 mg.
[0008] In some embodiments of any of the aspects, the composition or combination is formulated as one or more oral formulations. In some embodiments of any of the aspects, the composition or combination is formulated as an oral formulation. In some embodiments of any of the aspects, the oral formulation is a pill, tablet, capsule, chewable formulation, orally disintegrating formulation, powder, pellet, liquid, syrup, solution, or drop. In some embodiments of any of the aspects, the oral24928-7411-2416 2Attorney Docket No: 105619-000001WOPTformulation is a pill, tablet, capsule, chewable formulation, and / or an orally disintegrating formulation. In some embodiments of any of the aspects, the oral formulation is a gastro-resistant pill, gastro-resistant tablet, or gastro-resistant capsule.
[0009] In one aspect of any of the embodiments, described herein is a method of treating a geriatric syndrome in a subject in need thereof, the method comprising administering a composition or combination as described herein. In some embodiments of any of the aspects, the geriatric syndrome is selected from the group consisting of: sarcopenia, chronic kidney disease, neurodegenerative disease, musculoskeletal disorder, and myelodysplastic syndrome. In some embodiments of any of the aspects, the geriatric syndrome is sarcopenia.
[0010] In one aspect of any of the embodiments, described herein is a method of increasing longevity in a subject, the method comprising administering a composition or combination described herein.
[0011] In one aspect of any of the embodiments, described herein is a method of reducing geriatric frailty or reducing the rate of increase of geriatric frailty in a subject, the method comprising administering a composition or combination of any one of the preceding claims.
[0012] In some embodiments of any of the aspects, the method is not a method for treatment of the human or animal body by surgery or therapy practiced on the human or animal body.
[0013] In some embodiments of any of the aspects, the subject is a feline. In some embodiments of any of the aspects, the subject is geriatric. In some embodiments of any of the aspects, the subject is a feline of at least 10 years of age. In some embodiments of any of the aspects, the composition or combination is administered every 3-10 days. In some embodiments of any of the aspects, the composition or combination is administered weekly.BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figs.1A-1B depict levels of indicated biomarkers in cats treated as described in Example 1.
[0015] Figs. 2A-2D depict cell culture experiments demonstrating that that PURR-001 signatures can be distinct or amplified from those of its individual components. PRRX1 (downregulated) and TGM2 (upregulated) are some of the genes that display synergistic responses in omic screens from feline cell lines to PURR-001.
[0016] Fig. 3 demonstrates that in a randomized double-blind clinical trial, sarcopenic cats given PURR-001 gained more weight than sarcopenic cats given placebo (microcrystalline cellulose) at the 6 weeks timepoint. On average, placebo-treated cats increased in weight by 3.45%, while PURR-001-treated cats increased in weight 8.94%. Figs. 4A-4B demonstrate that PURR-001 treatment increases epaxial muscle thickness in sarcopenic elderly cats, as determined by ultrasound profiling of epaxial muscle group thickness. In this particular case, the cat increased in weight considerably (several34928-7411-2416 2Attorney Docket No: 105619-000001WOPThundred grams) and also increased its epaxial muscle thickness by 16.45% (from an average readout of 15.2 mm to 17.7 mm). Fig. 4A depicts the cat before treatment, Fig. 4B after treatment.
[0017] Figs. 5A-5B demonstrate that PURR-001 oral capsules are well tolerated and safe in sarcopenic elderly cats over the course of 12 weeks. No significant changes are observed in renal (creatinine (Fig. 5B) or hepatic (albumin (Fig. 5A) in dozens of cats given PURR-001 or placebo. Fighter grey series is PURR-001, darker grey series is the placebo control.DETAILED DESCRIPTION
[0018] The inventors have found that combinations of multiple therapeutics can reverse symptoms of aging including sarcopenia, weight loss, and multiple biomarkers of aging and poor geriatric outcomes. Accordingly, described herein are compositions and combinations that can treat, reduce, or prevent geriatric syndromes and geriatric frailty, or prolong longevity.
[0019] In one aspect of any of the embodiments, described herein is a composition or combination comprising at least two of:a) at least one mTOR inhibitor;b) mirtazapine;c) at least one of acarbose and metformin;d) glycine; ande) N-acetyl-L-cysteine.
[0020] In some embodiments of any of the aspects, described herein is a composition or combination consisting essentially of at least two of: a) at least one mTOR inhibitor; b) mirtazapine; c) at least one of acarbose and metformin; d) glycine; and e) N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination consisting of at least two of: a) at least one mTOR inhibitor; b) mirtazapine; c) at least one of acarbose and metformin; d) glycine; and e) N-acetyl-L-cysteine.
[0021] In some embodiments of any of the aspects, described herein is a composition or combination comprising at least three of:a) at least one mTOR inhibitor;b) mirtazapine;c) at least one of acarbose and metformin;d) glycine; ande) N-acetyl-L-cysteine.
[0022] In some embodiments of any of the aspects, described herein is a composition or combination comprising at least four of:a) at least one mTOR inhibitor;b) mirtazapine;44928-7411-2416 2Attorney Docket No: 105619-000001WOPTc) at least one of acarbose and metformin;d) glycine; ande) N-acetyl-L-cysteine.
[0023] In some embodiments of any of the aspects, described herein is a composition or combination comprising:a) at least one mTOR inhibitor;b) mirtazapine;c) at least one of acarbose and metformin;d) glycine; ande) N-acetyl-L-cysteine.
[0024] In some embodiments of any of the aspects, described herein is a composition or combination comprising at least two of: a) at least one mTOR inhibitor; b) mirtazapine; c) acarbose; d) glycine; and e) N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least two of: a) at least one mTOR inhibitor; b) mirtazapine; c) metformin; d) glycine; and e) N-acetyl-L-cysteine.
[0025] In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor and mirtazapine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor and acarbose. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine and acarbose. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising acarbose and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising acarbose and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising glycine and N-acetyl-L-cysteine.
[0026] In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor and mirtazapine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor and metformin. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at54928-7411-2416 2Attorney Docket No: 105619-000001WOPTleast one mTOR inhibitor and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine and metformin. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising metformin and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising metformin and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising glycine and N-acetyl-L-cysteine.
[0027] In some embodiments of any of the aspects, described herein is a composition or combination comprising at least three of: a) at least one mTOR inhibitor; b) mirtazapine; c) acarbose; d) glycine; and e) N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least three of: a) at least one mTOR inhibitor; b) mirtazapine; c) metformin; d) glycine; and e) N-acetyl-L-cysteine.
[0028] In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, mirtazapine, and acarbose. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, mirtazapine, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, mirtazapine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, acarbose, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, acarbose, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, glycine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, acarbose, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, acarbose, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, glycine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising acarbose, glycine, and N-acetyl-L-cysteine.
[0029] In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, mirtazapine, and metformin. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, mirtazapine, and glycine. In some embodiments of any of the aspects,64928-7411-2416 2Attorney Docket No: 105619-000001WOPTdescribed herein is a composition or combination comprising at least one mTOR inhibitor, mirtazapine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, metformin, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, metformin, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, glycine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, metformin, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, metformin, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, glycine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising metformin, glycine, and N-acetyl-L-cysteine.
[0030] In some embodiments of any of the aspects, described herein is a composition or combination comprising at least four of: a) at least one mTOR inhibitor; b) mirtazapine; c) acarbose; d) glycine; and e) N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least four of: a) at least one mTOR inhibitor; b) mirtazapine; c) metformin; d) glycine; and e) N-acetyl-L-cysteine.
[0031] In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, mirtazapine, acarbose, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, mirtazapine, acarbose, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, mirtazapine, glycine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, acarbose, glycine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, acarbose, and glycine, and N-acetyl-L-cysteine.
[0032] In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, mirtazapine, metformin, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, mirtazapine, metformin, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, mirtazapine, glycine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, metformin, glycine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a74928-7411-2416 2Attorney Docket No: 105619-000001WOPTcomposition or combination comprising mirtazapine, metformin, and glycine, and N-acetyl-L-cysteine.
[0033] In some embodiments of any of the aspects, described herein is a composition or combination comprising: a) at least one mTOR inhibitor; b) mirtazapine; c) acarbose; d) glycine; and e) N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising: a) at least one mTOR inhibitor; b) mirtazapine; c) metformin; d) glycine; and e) N-acetyl-L-cysteine.
[0034] In some embodiments of any of the aspects, described herein is a composition or combination comprising: at least one mTOR inhibitor, mirtazapine, acarbose, metformin, glycine, and N-acetyl-L-cysteine .
[0035] In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, acarbose, and metformin. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, acarbose, and metformin. In some embodiments of any of the aspects, described herein is a composition or combination comprising acarbose, metformin, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising acarbose, metformin, and N-acetyl-L-cysteine.
[0036] In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, mirtazapine, acarbose, and metformin. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, acarbose, metformin, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, acarbose, metformin, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, acarbose, metformin, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, acarbose, metformin, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising acarbose, metformin, glycine, and N-acetyl-L-cysteine.
[0037] In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, mirtazapine, acarbose, metformin, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, mirtazapine, acarbose, metformin, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least one mTOR inhibitor, acarbose, metformin, glycine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, acarbose, metformin, and glycine, and N-acetyl-L-cysteine.84928-7411-2416 2Attorney Docket No: 105619-000001WOPT
[0038] As used herein, “mTOR” or “mammalian target of rapamycin” refers to a protein kinase that controls cellular metabolism, catabolism, immune responses, autophagy, survival, proliferation, and migration, to maintain cellular homeostasis via signal cascade involving mTOR complex 1 / 2 (mTORCl / 2), AKT, protein kinase C, insulin growth factor receptor (IGF-1R), 4E binding protein 1 (4E-BP1), ribosomal protein S6 kinase (S6K), transcription factor EB (TFEB), sterol-responsive element-binding proteins (SREBPs), Lipin-1, and Unc-51-like autophagy-activating kinases. See, e.g., Panwar et al. Signal Transduction and Targeted Therapy 8:375 (2023); which is incorporated by reference herein in its entirety.
[0039] As used herein, “inhibitor” refers to an agent which can decrease the expression and / or activity of a target, e.g. by at least 10% or more, e.g. by 10% or more, 50% or more, 70% or more, 80% or more, 90% or more, 95% or more, or 98 % or more. The efficacy of an inhibitor of one or more targets, e.g. its ability to decrease the level and / or activity of the target can be determined, e.g. by measuring the level of an expression product of the target and / or the activity of the target. In some embodiments of any of the aspects, the inhibitor can be an inhibitory nucleic acid; an aptamer; an antibody reagent; an antibody; or a small molecule. An inhibitor of a target described herein can inhibit the activity, expression, or accumulation of the target polypeptide. Inhibitors can include inhibitors that act directly on the target itself (e.g., that bind to the protein or transcript, e.g., direct inhibitors). In some embodiments of any of the aspects, an inhibitor of a specified target is an antibody, antibody reagent, or antigen-binding fragment thereof, that specifically binds to the target.
[0040] Exemplary mTOR inhibitors are known in the art and can include, but are not limited to everolimus, temsirolimus, rapamycin, deforolimus, TOP216, OSI-027, TAFA93, nab-rapamycin, tacrolimus, biolimus, CI-779, ABT-578, AP-23675, BEZ-235, QLT-0447, ABI-009, BC-210, salirasib, AP-23841, AP-23573, KU-0059475, 32-deoxorapamycin, 16-pent-2-ynyloxy-32-deoxorapamycin, 16-pent-2-ynyloxy-32 (S or R)-dihydro-rapamycin, 16-pent-2-ynyloxy-32 (S or R)-dihydro-40-O-(2-hydroxyethyl)-rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, 32-deoxorapamycin; 16-pent-2-ynyloxy-32(S)-dihydrorapamycin; so called rapalogs; AP23464; PI-103, PP242, PP30, Torinl; and derivatives or pharmaceutically acceptable salts thereof as well as and compounds described in, e.g. U.S. Patent Publications 2011 / 0178070; 2011 / 0021515; 2007 / 0112005;2011 / 0054013; International Patent Publications WO98 / 02441; WOOl / 14387; WO99 / 15530;WO07 / 135411; WO03 / 64383; WO96 / 41807; WO95 / 16691; W094 / 09010; European Patent No. EP1880723; and U.S. Patent Nos. 8,163,775; 6,329,386; 6,200,985; 6,117,863; 6,015,815; 6,015,809; 6,004,973; 5,985,890; 5,955,457; 5,922,730; 5,912,253; 5,780,462; 5,665,772; 5,637,590; 5,567,709; 5,563,145; 5,559,122; 5,559,120; 5,559,119; 5,559,112; 5,550,133; 5,541,192; 5,541,191; 5,532,355; 5,530,121; 5,530,007; 5,525,610; 5,521,194; 5,519,031; 5,516,780; 5,508,399; 5,508,290; 5,508,286; 5,508,285; 5,504,291; 5,504,204; 5,491,231; 5,489,680; 5,489,595; 5,488,054; 5,486,524; 5,486,523; 5,486,522; 5,484,791; 5,484,790; 5,480,989; 5,480,988; 5,463,048; 5,446,048; 5,434,260; 5,411,967;94928-7411-2416 2Attorney Docket No: 105619-000001WOPT5,391,730; 5,389,639; 5,385,910; 5,385,909; 5,385,908; 5,378,836; 5,378,696; 5,373,014; 5,362,718; 5,358,944; 5,346,893; 5,344,833; 5,302,584; 5,262,424; 5,262,423; 5,260,300; 5,260,299; 5,233,036; 5,221,740; 5,221,670; 5,202,332; 5,194,447; 5,177,203; 5,169,851; 5,164,399; 5,162,333; 5,151,413; 5,138,051; 5,130,307; 5,120,842; 5,120,727; 5,120,726; 5,120,725; 5,118,678; 5,118,677; 5,100,883; 5,023,264; 5,023,263; and 5,023,262; which are incorporated by reference herein in their entireties.); rapamycin (sirolimus) or an analogue thereof (e.g. everolimus, temsirolimus, ridaforolimus, deforolimus); or an anti-proliferative agent (e.g. mycophenoloate moefitil, azathioprine). In some embodiments, the mTOR inhibitor can be rapamycin or an analogue thereof, e.g. everolimus, temsirolimus, ridaforolimus, or deforolimus.
[0041] In some embodiments of any of the aspects, the at least one mTOR inhibitor comprises rapamycin. In some embodiments of any of the aspects, the at least one mTOR inhibitor consists of rapamycin. In some embodiments of any of the aspects, the at least one mTOR inhibitor consists essentially of rapamycin. In some embodiments of any of the aspects, the at least one mTOR inhibitor is rapamycin.
[0042] In one aspect of any of the embodiments, described herein is a composition or combination comprising at least two of:a) rapamycin;b) mirtazapine;c) at least one of acarbose and metformin;d) glycine; ande) N-acetyl-L-cysteine.
[0043] In some embodiments of any of the aspects, described herein is a composition or combination consisting essentially of at least two of: a) rapamycin; b) mirtazapine; c) at least one of acarbose and metformin; d) glycine; and e) N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination consisting of at least two of: a) rapamycin; b) mirtazapine; c) at least one of acarbose and metformin; d) glycine; and e) N-acetyl-L-cysteine.
[0044] In some embodiments of any of the aspects, described herein is a composition or combination comprising at least three of:a) rapamycin;b) mirtazapine;c) at least one of acarbose and metformin;d) glycine; ande) N-acetyl-L-cysteine.
[0045] In some embodiments of any of the aspects, described herein is a composition or combination comprising at least four of:a) rapamycin;104928-7411-2416 2Attorney Docket No: 105619-000001WOPTb) mirtazapine;c) at least one of acarbose and metformin;d) glycine; ande) N-acetyl-L-cysteine.
[0046] In some embodiments of any of the aspects, described herein is a composition or combination comprising:a) rapamycin;b) mirtazapine;c) at least one of acarbose and metformin;d) glycine; ande) N-acetyl-L-cysteine.
[0047] In some embodiments of any of the aspects, described herein is a composition or combination comprising at least two of: a) rapamycin; b) mirtazapine; c) acarbose; d) glycine; and e) N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least two of: a) rapamycin; b) mirtazapine; c) metformin; d) glycine; and e) N-acetyl-L-cysteine.
[0048] In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin and mirtazapine. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin and acarbose. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine and acarbose. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising acarbose and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising acarbose and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising glycine and N-acetyl-L-cysteine.
[0049] In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin and mirtazapine. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin and metformin. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin and glycine. In some embodiments of any of the aspects, described herein is a composition114928-7411-2416 2Attorney Docket No: 105619-000001WOPTor combination comprising rapamycin and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine and metformin. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising metformin and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising metformin and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising glycine and N-acetyl-L-cysteine.
[0050] In some embodiments of any of the aspects, described herein is a composition or combination comprising at least three of: a) rapamycin; b) mirtazapine; c) acarbose; d) glycine; and e) N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least three of: a) rapamycin; b) mirtazapine; c) metformin; d) glycine; and e) N-acetyl-L-cysteine.
[0051] In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, mirtazapine, and acarbose. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, mirtazapine, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, mirtazapine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, acarbose, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, acarbose, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, glycine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, acarbose, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, acarbose, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, glycine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising acarbose, glycine, and N-acetyl-L-cysteine .
[0052] In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, mirtazapine, and metformin. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, mirtazapine, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, mirtazapine, and N-acetyl-L-cysteine. In some embodiments of any of the124928-7411-2416 2Attorney Docket No: 105619-000001WOPTaspects, described herein is a composition or combination comprising rapamycin, metformin, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, metformin, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, glycine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, metformin, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, metformin, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, glycine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising metformin, glycine, and N-acetyl-L-cysteine.
[0053] In some embodiments of any of the aspects, described herein is a composition or combination comprising at least four of: a) rapamycin; b) mirtazapine; c) acarbose; d) glycine; and e) N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising at least four of: a) rapamycin; b) mirtazapine; c) metformin; d) glycine; and e) N-acetyl-L-cysteine.
[0054] In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, mirtazapine, acarbose, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, mirtazapine, acarbose, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, mirtazapine, glycine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, acarbose, glycine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, acarbose, and glycine, and N-acetyl-L-cysteine.
[0055] In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, mirtazapine, metformin, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, mirtazapine, metformin, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, mirtazapine, glycine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, metformin, glycine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, metformin, and glycine, and N-acetyl-L-cysteine.
[0056] In some embodiments of any of the aspects, described herein is a composition or combination comprising: a) rapamycin; b) mirtazapine; c) acarbose; d) glycine; and e) N-acetyl-L-134928-7411-2416 2Attorney Docket No: 105619-000001WOPTcysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising: a) rapamycin; b) mirtazapine; c) metformin; d) glycine; and e) N-acetyl-L-cysteine.
[0057] In some embodiments of any of the aspects, described herein is a composition or combination comprising: rapamycin, mirtazapine, acarbose, metformin, glycine, and N-acetyl-L-cysteine.
[0058] In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, acarbose, and metformin. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, acarbose, and metformin. In some embodiments of any of the aspects, described herein is a composition or combination comprising acarbose, metformin, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising acarbose, metformin, and N-acetyl-L-cysteine .
[0059] In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, mirtazapine, acarbose, and metformin. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, acarbose, metformin, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, acarbose, metformin, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, acarbose, metformin, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, acarbose, metformin, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising acarbose, metformin, glycine, and N-acetyl-L-cysteine.
[0060] In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, mirtazapine, acarbose, metformin, and glycine. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, mirtazapine, acarbose, metformin, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising rapamycin, acarbose, metformin, glycine, and N-acetyl-L-cysteine. In some embodiments of any of the aspects, described herein is a composition or combination comprising mirtazapine, acarbose, metformin, and glycine, and N-acetyl-L-cysteine.
[0061] As used herein “combination” refers to a group of two or more substances or elements for use together, e.g., for use in treating a condition described herein. The two or more substances can be present in the same formulation in any molecular or physical arrangement, e.g., in an admixture, in a solution, in a mixture, in a suspension, in a colloid, in an emulsion. The formulation can be a homogeneous or heterogenous mixture. In some embodiments of any of the aspects, the two or more144928-7411-2416 2Attorney Docket No: 105619-000001WOPTsubstances can be comprised by the same or different superstructures, e.g., nanoparticles, liposomes, vectors, cells, scaffolds, or the like, and said superstructure is in solution, mixture, admixture, suspension with a solvent, carrier, or some of the two or more substances. Alternatively, the two or more substances can be present in two or more separate formulations, e.g., in a kit or package comprising multiple formulations in separate containers, to be mixed or brought into contact with each other when treatment is to be performed.
[0062] In some embodiments, the elements of a combination are provided in the same formulation. In some embodiments, the elements of a combination are provided in separate formulations or containers.
[0063] In one aspect of any of the embodiments, described herein is a kit comprising at least two of a) rapamycin; b) mirtazapine; c) at least one of acarbose and metformin; d) glycine; and e) N-acetyl-L-cysteine, or any combination thereof described herein.
[0064] A kit is an assemblage of materials or components, including at least one element or reagent described herein. The exact nature of the components configured in the kit depends on its intended purpose. In some embodiments of any of the aspects, a kit includes instructions for use. “Instructions for use” typically include a tangible expression describing the technique to be employed in using the components of the kit, e.g., to administer to a patient. Still in accordance with the present invention, “instructions for use” may include a tangible expression describing the preparation of at least one element described herein, such as dilution, mixing, or dosing instructions, and the like, typically for an intended purpose. Optionally, the kit also contains other useful components, such as measuring tools, diluents, buffers, syringes, pharmaceutically acceptable carriers, or other useful paraphernalia as will be readily recognized by those of skill in the art.
[0065] The materials or components assembled in the kit can be provided to the practitioner stored in any convenient and suitable ways that preserve their operability and utility. For example, the components can be in dissolved, dehydrated, or lyophilized form; they can be provided at room, refrigerated or frozen temperatures. The components are typically contained in suitable packaging material(s). As employed herein, the phrase “packaging material” refers to one or more physical structures used to house the contents of the kit, such as inventive compositions and the like. The packaging material is constructed by well-known methods, preferably to provide a sterile, contaminant-free environment. The packaging may also preferably provide an environment that protects from light, humidity, and oxygen. As used herein, the term “package” refers to a suitable solid matrix or material such as glass, plastic, paper, foil, polyester (such as polyethylene terephthalate, or Mylar) and the like, capable of holding the individual kit components. Thus, for example, a package can be a glass vial used to contain suitable quantities of a composition containing a volume of at least one reagent described herein. The packaging material generally has an external label which indicates the contents and / or purpose of the kit and / or its components.154928-7411-2416 2Attorney Docket No: 105619-000001WOPT
[0066] In some embodiments of any of the aspects, a composition, combination, or kit described herein is for use in treating a geriatric syndrome. In some embodiments of any of the aspects, a composition, combination, or kit described herein is for use in treating geriatric frailty.
[0067] In some embodiments of any of the aspects, and composition or combination described herein consists of the active ingredients described herein, e.g., at least two of: a) rapamycin; b) mirtazapine; c) at least one of acarbose and metformin; d) glycine; and e) N-acetyl-L-cysteine and / or any combination thereof described herein. In some embodiments of any of the aspects, and composition or combination described herein consists essentially of the active ingredients described herein, e.g., at least two of: a) rapamycin; b) mirtazapine; c) at least one of acarbose and metformin; d) glycine; and e) N-acetyl-L-cysteine and / or any combination thereof described herein.
[0068] As used herein, rapamycin refers to a compound having the structure of Formula I or a prodrug, isomer, enantiomer, diastereomer, racemate, tautomer, derivative, or salt thereof. Methods of making rapamycin are known in the art. In some embodiments of any of the aspects, rapamycin is a compound having the structure of Formula I.Formula I
[0069] In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of about 0.1 mg to about 1 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of about 0.5 mg to about 1.5 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of about 0.1 mg to about 0.5 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of about 0.05 mg to about 2.0 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of about 0.2 mg to about 0.8 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of about 0.3 mg to about 0.7 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of about 0.4 mg to about 0.6 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of about 0.2 mg to about 0.4 mg. In some embodiments of any of the aspects, the 164928-7411-2416 2Attorney Docket No: 105619-000001WOPTrapamycin is provided at or present at a dosage of about 0.3 mg to about 0.5 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of about 0.5 mg to about 0.7 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of about 0.6 mg to about 0.8 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of about 0.7 mg to about 0.9 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of about 0.8 mg to about 1.0 mg. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation given on a weekly basis. In some embodiments of any of the aspects, the foregoing amounts are the amount per 4 kg per week.
[0070] In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of 0.1 mg to 1 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of 0.5 mg to 1.5 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of 0.1 mg to 0.5 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of 0.05 mg to 2.0 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of 0.2 mg to 0.8 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of 0.3 mg to 0.7 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of 0.4 mg to 0.6 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of 0.2 mg to 0.4 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of 0.3 mg to 0.5 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of 0.5 mg to 0.7 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of 0.6 mg to 0.8 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of 0.7 mg to 0.9 mg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of 0.8 mg to 1.0 mg. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation given on a weekly basis. In some embodiments of any of the aspects, the foregoing amounts are the amount per 4 kg per week.
[0071] In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of about 0.1 mg to about 1 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of about 0.5 mg to about 1.5 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of about 0.1 mg to about 0.5 mg. In some embodiments of any of the aspects, the at least174928-7411-2416 2Attorney Docket No: 105619-000001WOPTone mTOR inhibitor is provided at or present at a dosage of about 0.05 mg to about 2.0 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of about 0.2 mg to about 0.8 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of about 0.3 mg to about 0.7 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of about 0.4 mg to about 0.6 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of about 0.2 mg to about 0.4 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of about 0.3 mg to about 0.5 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of about 0.5 mg to about 0.7 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of about 0.6 mg to about 0.8 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of about 0.7 mg to about 0.9 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of about 0.8 mg to about 1.0 mg. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation given on a weekly basis. In some embodiments of any of the aspects, the foregoing amounts are the amount per 4 kg per week.
[0072] In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of 0.1 mg to 1 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of 0.5 mg to 1.5 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of 0.1 mg to 0.5 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of 0.05 mg to 2.0 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of 0.2 mg to 0.8 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of 0.3 mg to 0.7 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of 0.4 mg to 0.6 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of 0.2 mg to 0.4 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of 0.3 mg to 0.5 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of 0.5 mg to 0.7 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of 0.6 mg to 0.8 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at or present at a dosage of 0.7 mg to 0.9 mg. In some embodiments of any of the aspects, the at least one mTOR inhibitor is provided at184928-7411-2416 2Attorney Docket No: 105619-000001WOPTor present at a dosage of 0.8 mg to 1.0 mg. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation given on a weekly basis. In some embodiments of any of the aspects, the foregoing amounts are the amount per 4 kg per week.
[0073] As used herein, mirtazapine refers to a compound having the structure of Formula II or a prodrug, isomer, enantiomer, diastereomer, racemate, tautomer, derivative, or salt thereof. Methods of making mirtazapine are known in the art. In some embodiments of any of the aspects, mirtazapine is a compound having the structure of Formula II.Formula II
[0074] In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 1 mg to about 3 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 0.5 mg to about 2.5 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 2 mg to about 3 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 1 mg to about 2 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 0.5 mg to about 0.7 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 0.6 mg to about 0.8 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 0.7 mg to about 0.9 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 0.8 mg to about 1 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 0.9 mg to about 1.1 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 1 mg to about 1.2 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 1.1 mg to about 1.3 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 1.2 mg to about 1.4 mg. In some194928-7411-2416 2Attorney Docket No: 105619-000001WOPTembodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 1.3 mg to about 1.5 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 1.4 mg to about 1.6 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 1.5 mg to about 1.7 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 1.6 mg to about 1.8 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 1.9 mg to about 2.1 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 2 mg to about 2.2 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 2.1 mg to about 2.3 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 2.2 mg to about 2.4 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 2.3 mg to about 2.5 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 2.4 mg to about 2.6 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 2.5 mg to about 2.7 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 2.6 mg to about 2.8 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 2.7 mg to about 2.9 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of about 2.8 mg to about 3 mg. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation given on a weekly basis. In some embodiments of any of the aspects, the foregoing amounts are the amount per 4 kg per week.
[0075] In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 1 mg to 3 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 0.5 mg to 2.5 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 2 mg to 3 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 1 mg to 2 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 0.5 mg to 0.7 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 0.6 mg to 0.8 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 0.7 mg to 0.9 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 0.8 mg to 1 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 0.9 mg to 1.1 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 1 mg to 1.2 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 1.1 mg to204928-7411-2416 2Attorney Docket No: 105619-000001WOPT1.3 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 1.2 mg to 1.4 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 1.3 mg to 1.5 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 1.4 mg to 1.6 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 1.5 mg to 1.7 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 1.6 mg to 1.8 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 1.9 mg to 2.1 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 2 mg to 2.2 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 2.1 mg to 2.3 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 2.2 mg to 2.4 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 2.3 mg to 2.5 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 2.4 mg to 2.6 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 2.5 mg to 2.7 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 2.6 mg to 2.8 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 2.7 mg to 2.9 mg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 2.8 mg to 3 mg. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation given on a weekly basis. In some embodiments of any of the aspects, the foregoing amounts are the amount per 4 kg per week.
[0076] As used herein, acarbose refers to a compound having the structure of Formula III or a prodrug, isomer, enantiomer, diastereomer, racemate, tautomer, derivative, or salt thereof. Methods of making acarbose are known in the art. In some embodiments of any of the aspects, acarbose is a compound having the structure of Formula III.OH Me OH OHHO'HOFormula III214928-7411-2416 2Attorney Docket No: 105619-000001WOPT
[0077] In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 5 mg to about 20 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 1 mg to about 10 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 10 mg to about 30 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 1 mg to about 5 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 2 mg to about 6 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 3 mg to about 7 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 4 mg to about 8 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 5 mg to about 9 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 6 mg to about 10 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 7 mg to about 11 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 8 mg to about 12 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 9 mg to about 13 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 10 mg to about 14 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 11 mg to about 15 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 12 mg to about 16 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 13 mg to about 17 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 14 mg to about 18 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 15 mg to about 19 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 16 mg to about 20 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 17 mg to about 21 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 18 mg to about 22 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 19 mg to about 23 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 20 mg to about 24 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of about 21 mg to about 25 mg. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation given on a weekly basis. In some embodiments of any of the aspects, the foregoing amounts are the amount per 4 kg per week.224928-7411-2416 2Attorney Docket No: 105619-000001WOPT
[0078] In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 5 mg to 20 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 1 mg to 10 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 10 mg to 30 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 1 mg to 5 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 2 mg to 6 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 3 mg to 7 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 4 mg to 8 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 5 mg to 9 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 6 mg to 10 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 7 mg to 11 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 8 mg to 12 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 9 mg to 13 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 10 mg to 14 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 11 mg to 15 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 12 mg to 16 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 13 mg to 17 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 14 mg to 18 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 15 mg to 19 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 16 mg to 20 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 17 mg to 21 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 18 mg to 22 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 19 mg to 23 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 20 mg to 24 mg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 21 mg to 25 mg. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation given on a weekly basis. In some embodiments of any of the aspects, the foregoing amounts are the amount per 4 kg per week.
[0079] As used herein, metformin refers to a compound having the structure of Formula IV or a prodrug, isomer, enantiomer, diastereomer, racemate, tautomer, derivative, or salt thereof. Methods of making metformin are known in the art. In some embodiments of any of the aspects, metformin is a compound having the structure of Formula IV.234928-7411-2416 2Attorney Docket No: 105619-000001WOPTFormula IV
[0080] In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 1 mg to about 20 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 5 mg to about 20 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 5 mg to about 15 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 1 mg to about 10 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 10 mg to about 30 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 1 mg to about 5 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 2 mg to about 6 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 3 mg to about 7 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 4 mg to about 8 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 5 mg to about 9 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 6 mg to about 10 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 7 mg to about 11 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 8 mg to about 12 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 9 mg to about 13 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 10 mg to about 14 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 11 mg to about 15 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 12 mg to about 16 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 13 mg to about 17 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 14 mg to about 18 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 15 mg to about 19 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 16 mg to about 20 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 17 mg to about 21 mg. In some embodiments of any of the aspects, the metformin is provided at or present244928-7411-2416 2Attorney Docket No: 105619-000001WOPTat a dosage of about 18 mg to about 22 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 19 mg to about 23 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 20 mg to about 24 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of about 21 mg to about 25 mg. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation given on a weekly basis. In some embodiments of any of the aspects, the foregoing amounts are the amount per 4 kg per week.
[0081] In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 1 mg to 20 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 5 mg to 20 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 5 mg to 15 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 1 mg to 10 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 10 mg to 30 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 1 mg to 5 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 2 mg to 6 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 3 mg to 7 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 4 mg to 8 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 5 mg to 9 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 6 mg to 10 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 7 mg to 11 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 8 mg to 12 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 9 mg to 13 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 10 mg to 14 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 11 mg to 15 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 12 mg to 16 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 13 mg to 17 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 14 mg to 18 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 15 mg to 19 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 16 mg to 20 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 17 mg to 21 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 18 mg to 22 mg. In some embodiments of any of the aspects, the metformin is provided254928-7411-2416 2Attorney Docket No: 105619-000001WOPTat or present at a dosage of 19 mg to 23 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 20 mg to 24 mg. In some embodiments of any of the aspects, the metformin is provided at or present at a dosage of 21 mg to 25 mg. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation given on a weekly basis. In some embodiments of any of the aspects, the foregoing amounts are the amount per 4 kg per week.
[0082] As used herein, glycine refers to a compound having the structure of Formula V or a prodrug, isomer, enantiomer, diastereomer, racemate, tautomer, derivative, or salt thereof. Methods of making glycine are known in the art. In some embodiments of any of the aspects, glycine is a compound having the structure of Formula V.Formula V
[0083] In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of about 100 mg to about 400 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of about 200 mg to about 500 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of about 50 mg to about 300 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of about 100 mg to about 300 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of about 200 mg to about 400 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of about 300 mg to about 500 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of about 100 mg to about 200 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of about 150 mg to about 250 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of about 200 mg to about 300 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of about 250 mg to about 350 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of about 300 mg to about 400 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of about 350 mg to about 450 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of about 50 mg to about 100 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of about 100 mg to about 150 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of about 150 mg to about 200 mg. In some embodiments of any of the aspects, the glycine is provided at or present at264928-7411-2416 2Attorney Docket No: 105619-000001WOPTa dosage of about 200 mg to about 250 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of about 250 mg to about 300 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of about 300 mg to about 350 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of about 350 mg to about 450 mg. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation given on a weekly basis. In some embodiments of any of the aspects, the foregoing amounts are the amount per 4 kg per week.
[0084] In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 100 mg to 400 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 200 mg to 500 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 50 mg to 300 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 100 mg to 300 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 200 mg to 400 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 300 mg to 500 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 100 mg to 200 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 150 mg to 250 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 200 mg to 300 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 250 mg to 350 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 300 mg to 400 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 350 mg to 450 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 50 mg to 100 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 100 mg to 150 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 150 mg to 200 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 200 mg to 250 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 250 mg to 300 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 300 mg to 350 mg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 350 mg to 450 mg. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation given on a weekly basis. In some embodiments of any of the aspects, the foregoing amounts are the amount per 4 kg per week.274928-7411-2416 2Attorney Docket No: 105619-000001WOPT
[0085] As used herein, “N-acetyl-L-cysteine” refers to a compound having the structure of Formula VI or a prodrug, isomer, enantiomer, diastereomer, racemate, tautomer, derivative, or salt thereof. N-acetyl-L-cysteine is also known in the art as A'-acctylcystcinc. Acetylcysteine, and NAC. Methods of making N-acetyl-L-cysteine are known in the art. In some embodiments of any of the aspects, N-acetyl-L-cysteine is a compound having the structure of Formula VI.Formula VI
[0086] In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of about 100 mg to about 400 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of about 200 mg to about 500 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of about 50 mg to about 300 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of about 100 mg to about 300 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of about 200 mg to about 400 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of about 300 mg to about 500 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of about 100 mg to about 200 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of about 150 mg to about 250 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of about 200 mg to about 300 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of about 250 mg to about 350 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of about 300 mg to about 400 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of about 350 mg to about 450 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of about 50 mg to about 100 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of about 100 mg to about 150 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of about 150 mg to about 200 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of about 200 mg to about 250 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of about 250 mg to about 300 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of about 300 mg to about 350 mg. In some284928-7411-2416 2Attorney Docket No: 105619-000001WOPTembodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of about 350 mg to about 450 mg. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation given on a weekly basis. In some embodiments of any of the aspects, the foregoing amounts are the amount per 4 kg per week.
[0087] In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 100 mg to 400 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 200 mg to 500 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 50 mg to 300 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 100 mg to 300 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 200 mg to 400 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 300 mg to 500 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 100 mg to 200 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 150 mg to 250 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 200 mg to 300 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 250 mg to 350 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 300 mg to 400 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 350 mg to 450 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 50 mg to 100 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 100 mg to 150 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 150 mg to 200 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 200 mg to 250 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 250 mg to 300 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 300 mg to 350 mg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 350 mg to 450 mg. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation given on a weekly basis. In some embodiments of any of the aspects, the foregoing amounts are the amount per 4 kg per week.294928-7411-2416 2Attorney Docket No: 105619-000001WOPT
[0088] In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 12.5 to 50 mg / kg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 1 to 100 mg / kg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 12.5 to 50 mg / kg. In some embodiments of any of the aspects, the glycine is provided at or present at a dosage of 1 to 100 mg / kg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 1.25 to 5 mg / kg. In some embodiments of any of the aspects, the acarbose is provided at or present at a dosage of 0.1 to 10 mg / kg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 0.25 to 1 mg / kg. In some embodiments of any of the aspects, the mirtazapine is provided at or present at a dosage of 0.01 to 2 mg / kg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of 0.0625 to 0.25 mg / kg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of 0.01 to 1 mg / kg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 12.5 to 50 mg / kg, the glycine is provided at or present at a dosage of 12.5 to 50 mg / kg, the acarbose is provided at or present at a dosage of 1.25 to 5 mg / kg, the mirtazapine is provided at or present at a dosage of 0.25 to 1 mg / kg, and / or the rapamycin is provided at or present at a dosage of 0.0625 to 0.25 mg / kg. In some embodiments of any of the aspects, the rapamycin is provided at or present at a dosage of 0.01 to 1 mg / kg. In some embodiments of any of the aspects, the N-acetyl-L-cysteine is provided at or present at a dosage of 12.5 to 50 mg / kg, the glycine is provided at or present at a dosage of 12.5 to 50 mg / kg, the acarbose is provided at or present at a dosage of 1.25 to 5 mg / kg, the mirtazapine is provided at or present at a dosage of 0.25 to 1 mg / kg, and the rapamycin is provided at or present at a dosage of 0.0625 to 0.25 mg / kg. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation. In some embodiments of any of the aspects, the foregoing amounts are the amount per pill, tablet, capsule or other dosage formulation given on a weekly basis. In some embodiments of any of the aspects, the foregoing amounts are the mg / kg per week.
[0089] The term “prodrug” as used herein refers to compounds that can be converted via some chemical or physiological process (e.g., enzymatic processes and metabolic hydrolysis) to compound described herein. Thus, the term “prodrug” also refers to a precursor of a biologically active compound that is pharmaceutically acceptable. A prodrug can be inactive when administered to a subject, i.e. an ester, but is converted in vivo to an active compound, for example, by hydrolysis to the free carboxylic acid or free hydroxyl. The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in an organism. The term “prodrug” is also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a subject. Prodrugs of an active compound, as described herein, may be prepared by modifying functional groups present in the active compound in such a way that the modifications are304928-7411-2416 2Attorney Docket No: 105619-000001WOPTcleaved, either in routine manipulation or in vivo, to the parent active compound. Prodrugs include compounds wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. For example, a compound comprising a hydroxy group can be administered as an ester that is converted by hydrolysis in vivo to the hydroxy compound. Suitable esters that can be converted in vivo into hydroxy compounds include acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, formates, benzoates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates, quinates, esters of amino acids, and the like. Similarly, a compound comprising an amine group can be administered as an amide, e.g., acetamide, formamide and benzamide that is converted by hydrolysis in vivo to the amine compound. See Harper, “Drug Latentiation” in Jucker, ed. Progress in Drug Research 4:221-294 (1962); Morozowich et al, “Application of Physical Organic Principles to Prodrug Design” in E. B. Roche ed. Design of Biopharmaceutical Properties through Prodrugs and Analogs, APHA Acad. Pharm. Sci. 40 (1977); Bioreversible Carriers in Drug in Drug Design, Theory and Application, E. B. Roche, ed., APHA Acad. Pharm. Sci. (1987); Design of Prodrugs, H. Bundgaard, Elsevier (1985); Wang et al. “Prodrug approaches to the improved delivery of peptide drug” in Curr. Pharm. Design. 5(4):265-287 (1999); Pauletti et al. (1997) Improvement in peptide bioavailability: Peptidomimetics and Prodrug Strategies, Adv. Drug. Delivery Rev. 27:235-256; Mizen et al. (1998) “The Use of Esters as Prodrugs for Oral Delivery of (3-Lactam antibiotics,” Pharm. Biotech. 11,: 345-365 ; Gaignault et al. (1996) “Designing Prodrugs and Bioprecursors I. Carrier Prodrugs,” Pract. Med. Chem. 671-696; Asghamejad, “Improving Oral Drug Transport”, in Transport Processes in Pharmaceutical Systems, G. L. Amidon, P. I. Lee and E. M. Topp, Eds., Marcell Dekker, p. 185-218 (2000); Balant et al., “Prodrugs for the improvement of drug absorption via different routes of administration”, Eur. J. Drug Metab. Pharmacokinet., 15(2): 143-53 (1990); Balimane and Sinko, “Involvement of multiple transporters in the oral absorption of nucleoside analogues”, Adv. Drug Delivery Rev., 39(1-3): 183-209 (1999); Browne, “Fosphenytoin (Cerebyx)”, Clin.Neuropharmacol. 20(1): 1-12 (1997); Bundgaard, “Bioreversible derivatization of drugs — principle and applicability to improve the therapeutic effects of drugs”, Arch. Pharm. Chemi 86(1): 1-39 (1979); Bundgaard H. “Improved drug delivery by the prodrug approach”, Controlled Drug Delivery 17: 179-96 (1987); Bundgaard H. “Prodrugs as a means to improve the delivery of peptide drugs”, Arfv. Drug Delivery Rev. 8(1): 1-38 (1992); Fleisher et al. “Improved oral drug delivery: solubility limitations overcome by the use of prodrugs”, Arfv. Drug Delivery Rev. 19(2): 115-130 (1996); Fleisher et al. “Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting”, Methods Enzymol. 112 (Drug Enzyme Targeting, Pt. A): 360-81, (1985); Farquhar D, et al., “Biologically Reversible Phosphate-Protective Groups”, Pharm. Sci., 72(3): 324-325 (1983);314928-7411-2416 2Attorney Docket No: 105619-000001WOPTFreeman S, et al., “Bioreversible Protection for the Phospho Group: Chemical Stability and Bioactivation of Di(4-acetoxy-benzyl) Methylphosphonate with Carboxyesterase,” Chem. Soc., Chem. Commun., 875-877 (1991); Friis and Bundgaard, “Prodrugs of phosphates and phosphonates: Novel lipophilic alphaacyloxyalkyl ester derivatives of phosphate- or phosphonate containing drugs masking the negative charges of these groups”, Eur. J. Pharm. Sci. 4: 49-59 (1996); Gangwar et al., “Pro-drug, molecular structure and percutaneous delivery”, Des. Biopharm. Prop. Prodrugs Analogs, [Symp.] Meeting Date 1976, 409-21. (1977); Nathwani and Wood, “Penicillins: a current review of their clinical pharmacology and therapeutic use”, Drugs 45(6): 866-94 (1993); Sinhababu and Thakker, “Prodrugs of anticancer agents”, Adv. Drug Delivery Rev. 19(2): 241-273 (1996); Stella et al., “Prodrugs. Do they have advantages in clinical practice?”, Drugs 29(5): 455-73 (1985); Tan et al. “Development and optimization of anti-HIV nucleoside analogs and prodrugs: A review of their cellular pharmacology, structure -activity relationships and pharmacokinetics”, Adv. Drug Delivery Rev. 39(1-3): 117-151 (1999); Taylor, “Improved passive oral drug delivery via prodrugs”, Adv. Drug Delivery Rev., 19(2): 131-148 (1996); Valentino and Borchardt, “Prodrug strategies to enhance the intestinal absorption of peptides”, Drug Discovery Today 2(4): 148-155 (1997); Wiebe and Knaus, “Concepts for the design of anti-HIV nucleoside prodrugs for treating cephalic HIV infection”, Adv. Drug Delivery Rev.: 39(1-3) : 63-80 (1999); Waller et al., “Prodrugs”, Br. J. Clin. Pharmac. 28: 497-507 (1989), content of all of which are herein incorporated by reference in its entirety.
[0090] A “pharmaceutically acceptable salt”, as used herein, is intended to encompass any compound described herein that is utilized in the form of a salt thereof, especially where the salt confers on the compound improved pharmacokinetic properties as compared to the free form of compound or a different salt form of the compound. The pharmaceutically acceptable salt form can also initially confer desirable pharmacokinetic properties on the compound that it did not previously possess, and may even positively affect the pharmacodynamics of the compound with respect to its therapeutic activity in the body. An example of a pharmacokinetic property that can be favorably affected is the manner in which the compound is transported across cell membranes, which in turn may directly and positively affect the absorption, distribution, biotransformation and excretion of the compound. While the route of administration of the pharmaceutical composition is important, and various anatomical, physiological and pathological factors can critically affect bioavailability, the solubility of the compound is usually dependent upon the character of the particular salt form thereof, which it utilized. One of skill in the art will appreciate that an aqueous solution of the compound will provide the most rapid absorption of the compound into the body of a subject being treated, while lipid solutions and suspensions, as well as solid dosage forms, will result in less rapid absorption of the compound.
[0091] Pharmaceutically acceptable salts include those derived from inorganic acids such as sulfuric, sulfamic, phosphoric, nitric, and the like; and the salts prepared from organic acids such as324928-7411-2416 2Attorney Docket No: 105619-000001WOPTacetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmitic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicyclic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isothionic, and the like. See, for example, Berge et al., “Pharmaceutical Salts”, J. Pharm. Sci. 66: 1-19 (1977), the content of which is herein incorporated by reference in its entirety. Exemplary salts also include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, succinate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like. Suitable acids which are capable of forming salts with the compounds of the disclosure include inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid, and the like; and organic acids such as 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, 2-naphthalenesulfonic acid, 3 -phenylpropionic acid, 4-methylbicyclo[2.2.2]oct-2-ene-l-carboxylic acid, 4,4’-mefhylenebis(3-hydroxy-2-ene-l-carboxylic acid), acetic acid, anthranilic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, cinnamic acid, citric acid, cyclopentanepropionic acid, ethanesulfonic acid, formic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, heptanoic acid, hydroxynaphthoic acid, lactic acid, lauryl sulfuric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, muconic acid , naphthalene sulfonic acid, o-(4-hydroxybenzoyl)benzoic acid, oxalic acid, p-chlorobenzenesulfonic acid, propionic acid, p-toluenesulfonic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, tertiary butylacetic acid, trifluoroacetic acid, trimethylacetic acid, and the like. Suitable bases capable of forming salts with the compounds of the disclosure include inorganic bases such as sodium hydroxide, ammonium hydroxide, sodium carbonate, calcium hydroxide, potassium hydroxide and the like; and organic bases such as mono-, di- and tri-alkyl and aryl amines (e.g., triethylamine, diisopropyl amine, methyl amine, dimethyl amine, N-methylglucamine, pyridine, picoline, dicyclohexylamine, N,N’-dibezylethylenediamine, and the like), and optionally substituted ethanol-amines (e.g., ethanolamine, diethanolamine, trierhanolamine and the like).
[0092] In some embodiments of any of the aspects, a composition or combination described herein can further comprise a dye or flavoring. Suitable dyes and flavorings are known in the art, e.g., iron oxide pigments or beet powder to provide a red or brown dye hue; and beef, salmon, chicken, tuna, and / or liver flavors. Methods of making such dyes and flavorings are known in the art. In some embodiments of any of the aspects, the composition or combination described herein does not comprise xylitol. In some embodiments of any of the aspects, the composition or combination described herein does not comprise peanut butter.
[0093] In some embodiments, the methods described herein relate to treating a subject having or diagnosed as having a geriatric syndrome, e.g., sarcopenia with a composition or combination334928-7411-2416 2Attorney Docket No: 105619-000001WOPTdescribed herein. Subjects having sarcopenia can be identified by a physician using current methods of diagnosing sarcopenia. Symptoms and / or complications of sarcopenia which characterize these conditions and aid in diagnosis are well known in the art and include but are not limited to, loss of stamina, difficulty with daily activities, slowed walking, trouble traversing stairs, poor balance, falls, and decreased muscle size. Tests that may aid in a diagnosis of, e.g. sarcopenia include, but are not limited to, physical tests, muscle strength tests, Dual-energy X-ray absorptiometry (DEXA or DXA), Bioelectrical impedance analysis (BIA). A family history of sarcopenia or exposure to risk factors for sarcopenia can also aid in determining if a subject is likely to have sarcopenia or in making a diagnosis of sarcopenia.
[0094] In some embodiments of any of the aspects, the methods described herein relate to treating geriatric syndrome by administering a composition or combination described herein. In some embodiments of any of the aspects, the subject is a subject having a geriatric syndrome. In some embodiments of any of the aspects, the subject is a subject diagnosed as having a geriatric syndrome. As used herein “geriatric syndrome” refers to a common multifactorial health condition of the elderly. Geriatric syndromes and their diagnosis are known in the art, e.g., Inouye et al. J Am Geriatr Soc 55:780-791 (2007), Ward et al. UpToDate (2024) (available on the world wide web at uptodate.com / contents / comprehensive-geriatric-assessment) and Brown-O’Hara Journal of Legal Nurse Consulting 25:8 (2014); each of which is incorporated by reference herein in its entirety.Exemplary geriatric syndromes include but are not limited to delirium, osteoporosis, weight loss, dementia, falls, incontinence, frailty, pressure ulcers, functional decline, sarcopenia, chronic kidney disease, neurodegenerative disease, musculoskeletal disorder, and myelodysplastic syndrome.
[0095] In some embodiments of any of the aspects, the methods described herein relate to treating sarcopenia by administering a composition or combination described herein. In some embodiments of any of the aspects, the subject is a subject having sarcopenia. In some embodiments of any of the aspects, the subject is a subject diagnosed as having sarcopenia.
[0096] In some embodiments of any of the aspects, the methods described herein relate to treating chronic kidney disease by administering a composition or combination described herein. In some embodiments of any of the aspects, the subject is a subject having a chronic kidney disease. In some embodiments of any of the aspects, the subject is a subject diagnosed as having a chronic kidney disease. Chronic kidney disease is codes at 1716 is the Nationwide Veterinary Pet insurance Benefit Schedules, available at qec2.petinsurance .com / assets / pdf / Maj or_Medical_Benefit_Schedule_qec .pdf.
[0097] In some embodiments of any of the aspects, the methods described herein relate to treating neurodegenerative disease. In some embodiments of any of the aspects, the subject is a subject having a neurodegenerative disease. In some embodiments of any of the aspects, the subject is a subject diagnosed as having a neurodegenerative disease.344928-7411-2416 2Attorney Docket No: 105619-000001WOPT
[0098] In some embodiments of any of the aspects, the methods described herein relate to treating musculoskeletal disorder by administering a composition or combination described herein. In some embodiments of any of the aspects, the subject is a subject having a musculoskeletal disorder. In some embodiments of any of the aspects, the subject is a subject diagnosed as having a musculoskeletal disorder.
[0099] In some embodiments of any of the aspects, the methods described herein relate to treating myelodysplastic syndrome by administering a composition or combination described herein. In some embodiments of any of the aspects, the subject is a subject having a myelodysplastic syndrome. In some embodiments of any of the aspects, the subject is a subject diagnosed as having a myelodysplastic syndrome.
[0100] In some embodiments of any of the aspects, the methods described herein relate to a method of increasing longevity in a subject by administering a composition or combination described herein. In some embodiments of any of the aspects, the method is not a method for treatment of the human or animal body by surgery or therapy practiced on the human or animal body.
[0101] In some embodiments of any of the aspects, described herein is a method of reducing geriatric frailty or reducing the rate of increase in geriatric frailty in a subject, the method comprising administering a composition or combination described herein. In some embodiments of any of the aspects, described herein is a method of reducing geriatric frailty in a subject, the method comprising administering a composition or combination described herein. In some embodiments of any of the aspects, described herein is a method of reducing the rate of increase in geriatric frailty in a subject, the method comprising administering a composition or combination described herein. In some embodiments of any of the aspects, the method is not a method for treatment of the human or animal body by surgery or therapy practiced on the human or animal body.
[0102] In some embodiments of any of the aspects, described herein is a method of reducing geriatric frailty or reducing the rate of increase in geriatric frailty in a subject, the method comprising administering a composition or combination described herein. In some embodiments of any of the aspects, described herein is a method of treating geriatric frailty in a subject, the method comprising administering a composition or combination described herein. In some embodiments of any of the aspects, described herein is a method of reducing geriatric frailty in a subject, the method comprising administering a composition or combination described herein. In some embodiments of any of the aspects, described herein is a method of reducing the rate of increase in geriatric frailty in a subject, the method comprising administering a composition or combination described herein. In some embodiments of any of the aspects, the subject is a subject having geriatric frailty. In some embodiments of any of the aspects, the subject is a subject diagnosed as having geriatric frailty.
[0103] As used herein “geriatric frailty” refers to a state of increased vulnerability resulting from aging-associated decline in reserve and function across multiple physiologic systems such that the354928-7411-2416 2Attorney Docket No: 105619-000001WOPTability to cope with every day or acute stressors is comprised. In some embodiments, geriatric frailty exists when the subject exhibits at least three out of five phenotypic criteria indicating compromised energetics: low grip strength, low energy, slowed waking speed, low physical activity, and / or unintentional weight loss. Geriatric frailty and methods of diagnosing it are known in the art, e.g., Xue. Clin Geriatr Med 27: 1-15 (2011) and Chen et al. Clin Interv Aging 9:433-441 (2014); each of which is incorporated by reference herein in its entirety.
[0104] In some embodiments of any of the aspects, the subject is a feline. In some embodiments of any of the aspects, the subject is a geriatric subject. In some embodiments of any of the aspects, the subject is a geriatric feline. In some embodiments of any of the aspects, the subject is a feline of at least 9 years of age. In some embodiments of any of the aspects, the subject is a feline of at least 10 years of age. In some embodiments of any of the aspects, the subject is a feline of at least 11 years of age. In some embodiments of any of the aspects, the subject is a feline of at least 12 years of age. In some embodiments of any of the aspects, the subject is a feline of at least 13 years of age. In some embodiments of any of the aspects, the subject is a feline of at least 14 years of age. In some embodiments of any of the aspects, the subject is a feline of at least 15 years of age.
[0105] In some embodiments of any of the aspects, the subject is a human. In some embodiments of any of the aspects, the subject is a geriatric subject. In some embodiments of any of the aspects, the subject is a geriatric human. In some embodiments of any of the aspects, the subject is a human of at least 65 years of age. In some embodiments of any of the aspects, the subject is a human of at least 70 years of age. In some embodiments of any of the aspects, the subject is a human of at least 75 years of age.
[0106] In some embodiments of any of the aspects, the subject is a canine. In some embodiments of any of the aspects, the subject is a geriatric subject. In some embodiments of any of the aspects, the subject is a geriatric canine. In some embodiments of any of the aspects, the subject is a canine of at least 7 years of age. In some embodiments of any of the aspects, the subject is a canine of at least 8 years of age. In some embodiments of any of the aspects, the canine is a canine of at least 9 years of age. In some embodiments of any of the aspects, the subject is a canine of at least 10 years of age. In some embodiments of any of the aspects, the subject is a canine of at least 11 years of age. In some embodiments of any of the aspects, the subject is a canine of at least 12 years of age.
[0107] The compositions and methods described herein can be administered to a subject having or diagnosed as having a condition described herein. In some embodiments, the methods described herein comprise administering an effective amount of compositions described herein, e.g. a composition or combination as described herein to a subject in order to alleviate a symptom of the condition. As used herein, "alleviating a symptom" is ameliorating any condition or symptom associated with the condition. As compared with an equivalent untreated control, such reduction is by364928-7411-2416 2Attorney Docket No: 105619-000001WOPTat least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, 99% or more as measured by any standard technique.
[0108] In some embodiments of any of the aspects, the symptom is reduced muscle mass. In some embodiments of any of the aspects, the symptom is the rate of reduction of muscle mass. In some embodiments of any of the aspects, the symptom is the level of HSP. In some embodiments of any of the aspects, the symptom is a reduced level of HSP. In some embodiments of any of the aspects, the symptom is the rate of decrease of HSP levels. In some embodiments of any of the aspects, the symptom is the level of B cells and / or T cells. In some embodiments of any of the aspects, the symptom is the reduction of B cells and / or T cells. In some embodiments of any of the aspects, the symptom is the rate of reduction of B cells and / or T cells. In some embodiments of any of the aspects, the symptom is the level of CD69+ B cells and / or CD69+T cells. In some embodiments of any of the aspects, the symptom is the reduction of CD69+ B cells and / or CD69+ T cells. In some embodiments of any of the aspects, the symptom is the rate of reduction of CD69+ B cells and / or CD69+T cells.
[0109] A variety of means for administering the compositions described herein to subjects are known to those of skill in the art. Such methods can include, but are not limited to oral, parenteral, intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), pulmonary, cutaneous, topical, or injection. Administration can be local or systemic.
[0110] The term “effective amount" as used herein refers to the amount of a composition, combination, or active ingredient needed to alleviate at least one or more symptom of the disease or disorder, and relates to a sufficient amount of pharmacological composition to provide the desired effect. The term "therapeutically effective amount" therefore refers to an amount of a composition, combination, or active ingredient that is sufficient to provide a particular therapeutic effect when administered to a typical subject. An effective amount as used herein, in various contexts, would also include an amount sufficient to delay the development of a symptom of the disease, alter the course of a symptom disease (for example but not limited to, slowing the progression of a symptom of the disease), or reverse a symptom of the disease. Thus, it is not generally practicable to specify an exact “effective amount" . However, for any given case, an appropriate “effective amount" can be determined by one of ordinary skill in the art using only routine experimentation.
[0111] Effective amounts, toxicity, and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dosage can vary depending upon the dosage form employed and the route of administration utilized. The dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio LD50 / ED50. Compositions and methods that exhibit large therapeutic indices are preferred. A therapeutically effective dose can be estimated initially from cell374928-7411-2416 2Attorney Docket No: 105619-000001WOPTculture assays. Also, a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 ( / .<?.. the concentration of an active ingredient, which achieves a half-maximal inhibition of symptoms) as determined in cell culture, or in an appropriate animal model. Levels in plasma can be measured, for example, by high performance liquid chromatography. The effects of any particular dosage can be monitored by a suitable bioassay, e.g., assay for B cell, inflammatory, and / or HSP markers, among others. The dosage can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment.
[0112] In some embodiments, the technology described herein relates to a pharmaceutical composition comprising one or more of the active ingredients as described herein, and optionally a pharmaceutically acceptable carrier. In some embodiments, the active ingredients of the pharmaceutical composition comprises the active ingredients as described herein. In some embodiments, the active ingredients of the pharmaceutical composition consist essentially of the active ingredients as described herein. In some embodiments, the active ingredients of the pharmaceutical composition consist of the active ingredients as described herein. Pharmaceutically acceptable carriers and diluents include saline, aqueous buffer solutions, solvents and / or dispersion media. The use of such carriers and diluents is well known in the art. Some non-limiting examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as com starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, methylcellulose, ethyl cellulose, microcrystalline cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol (PEG); (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and / or polyanhydrides; (22) bulking agents, such as polypeptides and amino acids (23) semm component, such as semm albumin, HDL and LDL; (22) C2-C12 alcohols, such as ethanol; and (23) other non-toxic compatible substances employed in pharmaceutical formulations. Wetting agents, coloring agents, release agents, coating agents, sweetening agents, flavoring agents, perfuming agents, preservative and antioxidants can also be present in the formulation. The terms such as "excipient", "carrier", "pharmaceutically acceptable carrier" or the like are used interchangeably herein. In some embodiments, the carrier inhibits the degradation of the active ingredient as described herein.384928-7411-2416 2Attorney Docket No: 105619-000001WOPT
[0113] In some embodiments of any of the aspects, the composition or combination is formulated as one or more oral formulations. In some embodiments of any of the aspects, the composition or combination is formulated as an oral formulation.
[0114] In some embodiments, the amount of an element or ingredient is the amount per pill. In some embodiments, the amount of an element or ingredient is the amount per tablet. In some embodiments, the amount of an element or ingredient is the amount per capsule.
[0115] In some embodiments of any of the aspects, the composition or combination is formulated as one or more pills, tablets, capsules, chewable formulations, orally disintegrating formulations, powders, pellets, liquids, syrup, solutions, or drops. In some embodiments of any of the aspects, the composition or combination is formulated as a pill, tablet, capsule, chewable formulation, orally disintegrating formulation, powder, pellet, liquid, syrup, solution, or drop.
[0116] In some embodiments of any of the aspects, the composition or combination is formulated as one or more pills, tablets, capsules, chewable formulations, or orally disintegrating formulations. In some embodiments of any of the aspects, the composition or combination is formulated as a pill, tablet, capsule, chewable formulation, or orally disintegrating formulation.
[0117] In some embodiments of any of the aspects, the composition or combination is formulated as one or more pills, tablets, or capsules. In some embodiments of any of the aspects, the composition or combination is formulated as a pill, tablet, or capsule.
[0118] In some embodiments of any of the aspects, the composition or combination is formulated as one or more pills. In some embodiments of any of the aspects, the composition or combination is formulated as a pill.
[0119] In some embodiments of any of the aspects, the composition or combination is formulated as one or more tablets. In some embodiments of any of the aspects, the composition or combination is formulated as a tablet.
[0120] In some embodiments of any of the aspects, the composition or combination is formulated as one or more capsules. In some embodiments of any of the aspects, the composition or combination is formulated as a capsule.
[0121] In some embodiments of any of the aspects, the composition or combination is formulated as a gastro-resistant formulation. As used herein, “gastro-resistant” refers to a formulation comprising a coating, barrier, capsule, etc., that prevents or reduces dissolution or disintegration of the formulation in the gastric environment. In some embodiments of any of the aspects, a gastro-resistant formulation is resistant to dissolution or disintegration at the pH of the stomach (pH ~3) but will dissolve or disintegrate at the pH of the small intestine (pH ~7-9).
[0122] In some embodiments of any of the aspects the gastro-resistance is a level which prevents dissolution of the gastro-resistant coating, barrier, or capsule at 0.1 M HC1 for at least 60 minutes at 37+2 °C. In some embodiments of any of the aspects the gastro-resistance is a level which prevents394928-7411-2416 2Attorney Docket No: 105619-000001WOPTany detectable dissolution of the gastro-resistant coating, barrier, or capsule at 0.1 M HC1 for at least 60 minutes at 37+2 °C. In some embodiments of any of the aspects the gastro-resistance is a level which prevents dissolution of the gastro-resistant coating, barrier, or capsule at 0.1 M HC1 for at least 120 minutes at 37+2 °C. In some embodiments of any of the aspects the gastro-resistance is a level which prevents any detectable dissolution of the gastro-resistant coating, barrier, or capsule at 0.1 M HC1 for at least 120 minutes at 37+2 °C.
[0123] In some embodiments of any of the aspects, a gastro-resistant formulation can be a formulation with an enteric coating. Exemplary gastro-resistant formulations and / or enteric coatings are known in the art and can include, by way of non-limiting example, shellac, methyl acrylatemethacrylic acid copolymers, cellulose acetate phthalate (CAP), cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate (hypromellose acetate succinate), polyvinyl acetate phthalate (PVAP), methyl methacrylatemethacrylic acid copolymers, cellulose acetate trimellitate, sodium alginate, zein, an enteric coating aqueous solution (ethylcellulose, medium chain triglycerides [coconut], oleic acid, sodium alginate, stearic acid) (coated softgels).
[0124] In some embodiments of any of the aspects, the composition or combination is formulated as one or more gastro-resistant pills, gastro-resistant tablets, or gastro-resistant capsules. In some embodiments of any of the aspects, the composition or combination is formulated as a gastro-resistant pill, a gastro-resistant tablet, or a gastro-resistant capsule.
[0125] In some embodiments of any of the aspects, the composition or combination is formulated as one or more gastro-resistant pills. In some embodiments of any of the aspects, the composition or combination is formulated as a gastro-resistant pill.
[0126] In some embodiments of any of the aspects, the composition or combination is formulated as one or more gastro-resistant tablets. In some embodiments of any of the aspects, the composition or combination is formulated as a gastro-resistant tablet.
[0127] In some embodiments of any of the aspects, the composition or combination is formulated as one or more gastro-resistant capsules. In some embodiments of any of the aspects, the composition or combination is formulated as a gastro-resistant capsule.
[0128] In some embodiments, the pharmaceutical composition comprising the active ingredients as described herein can be a parenteral dose form. Since administration of parenteral dosage forms typically bypasses the patient's natural defenses against contaminants, parenteral dosage forms are preferably sterile or capable of being sterilized prior to administration to a patient. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions. In addition, controlled-release parenteral dosage forms can be404928-7411-2416 2Attorney Docket No: 105619-000001WOPTprepared for administration of a patient, including, but not limited to, DUROS®-type dosage forms and dose-dumping.
[0129] Suitable vehicles that can be used to provide parenteral dosage forms of the active ingredients as disclosed within are well known to those skilled in the art. Examples include, without limitation: sterile water; water for injection USP; saline solution; glucose solution; aqueous vehicles such as but not limited to, sodium chloride injection, Ringer's injection, dextrose Injection, dextrose and sodium chloride injection, and lactated Ringer's injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and propylene glycol; and non-aqueous vehicles such as, but not limited to, com oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate. Compounds that alter or modify the solubility of a pharmaceutically acceptable salt of an active ingredient as disclosed herein can also be incorporated into the parenteral dosage forms of the disclosure, including conventional and controlled-release parenteral dosage forms.
[0130] Pharmaceutical compositions comprising the active ingredients can also be formulated to be suitable for oral administration, for example as discrete dosage forms, such as, but not limited to, tablets (including without limitation scored or coated tablets), pills, caplets, capsules, chewable tablets, powder packets, cachets, troches, wafers, aerosol sprays, or liquids, such as but not limited to, syrups, elixirs, solutions or suspensions in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil emulsion. Such compositions contain a predetermined amount of the pharmaceutically acceptable salt of the disclosed compounds, and may be prepared by methods of pharmacy well known to those skilled in the art. See generally, Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams, and Wilkins, Philadelphia PA. (2005).
[0131] Conventional dosage forms generally provide rapid or immediate drug release from the formulation. Depending on the pharmacology and pharmacokinetics of the drug, use of conventional dosage forms can lead to wide fluctuations in the concentrations of the drug in a patient's blood and other tissues. These fluctuations can impact a number of parameters, such as dose frequency, onset of action, duration of efficacy, maintenance of therapeutic blood levels, toxicity, side effects, and the like. Advantageously, controlled-release formulations can be used to control a drug's onset of action, duration of action, plasma levels within the therapeutic window, and peak blood levels. In particular, controlled- or extended-release dosage forms or formulations can be used to ensure that the maximum effectiveness of a drug is achieved while minimizing potential adverse effects and safety concerns, which can occur both from under-dosing a drug (i.e., going below the minimum therapeutic levels) as well as exceeding the toxicity level for the drug. In some embodiments, the composition or combination can be administered in a sustained release formulation.
[0132] Controlled-release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled release counterparts. Ideally, the use of an optimally designed controlled-release preparation in medical treatment is characterized by a minimum of drug414928-7411-2416 2Attorney Docket No: 105619-000001WOPTsubstance being employed to cure or control the condition in a minimum amount of time. Advantages of controlled-release formulations include: 1) extended activity of the drug; 2) reduced dosage frequency; 3) increased patient compliance; 4) usage of less total drug; 5) reduction in local or systemic side effects; 6) minimization of drug accumulation; 7) reduction in blood level fluctuations; 8) improvement in efficacy of treatment; 9) reduction of potentiation or loss of drug activity; and 10) improvement in speed of control of diseases or conditions. Kim, Chemg-ju, Controlled Release Dosage Form Design, 2 (Technomic Publishing, Lancaster, Pa.: 2000).
[0133] Most controlled-release formulations are designed to initially release an amount of drug (active ingredient) that promptly produces the desired therapeutic effect, and gradually and continually release other amounts of drug to maintain this level of therapeutic or prophylactic effect over an extended period of time. In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body. Controlled-release of an active ingredient can be stimulated by various conditions including, but not limited to, pH, ionic strength, osmotic pressure, temperature, enzymes, water, and other physiological conditions or compounds.
[0134] A variety of known controlled- or extended-release dosage forms, formulations, and devices can be adapted for use with the salts and compositions of the disclosure. Examples include, but are not limited to, those described in U.S. Pat. Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5674,533; 5,059,595; 5,591 ,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; 5,733,566; and 6,365,185 Bl ; each of which is incorporated herein by reference. These dosage forms can be used to provide slow or controlled-release of one or more active ingredients using, for example, hydroxypropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems (such as OROS® (Alza Corporation, Mountain View, Calif. USA)), or a combination thereof to provide the desired release profde in varying proportions.
[0135] The methods described herein can further comprise administering a second agent and / or treatment to the subject, e.g. as part of a combinatorial therapy. By way of non-limiting example, if a subject is to be treated for a condition involving pain or inflammation according to the methods described herein, the subject can also be administered a second agent and / or treatment known to be beneficial for subjects suffering from pain or inflammation. Examples of such agents and / or treatments include, but are not limited to, non-steroidal anti-inflammatory drugs (NSAIDs - such as aspirin, ibuprofen, or naproxen); corticosteroids, including glucocorticoids (e.g. cortisol, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, and beclometasone); methotrexate; sulfasalazine; leflunomide; anti-TNF medications; cyclophosphamide; pro-resolving drugs; my cophenolate; or opiates (e.g. endorphins, enkephalins, and dynorphin), steroids, analgesics, barbiturates, oxycodone, morphine, lidocaine, and the like.424928-7411-2416 2Attorney Docket No: 105619-000001WOPT
[0136] In certain embodiments, an effective dose of a composition or combination comprising the active ingredients as described herein can be administered to a patient once. In certain embodiments, an effective dose of a composition or combination comprising the active ingredients can be administered to a patient repeatedly. In certain embodiments, an effective dose of a composition or combination comprising the active ingredients can be administered to a patient daily. In certain embodiments, an effective dose of a composition or combination comprising the active ingredients can be administered to a patient every 2 days. In certain embodiments, an effective dose of a composition or combination comprising the active ingredients can be administered to a patient every 3 days. In certain embodiments, an effective dose of a composition or combination comprising the active ingredients can be administered to a patient every 4 days. In certain embodiments, an effective dose of a composition or combination comprising the active ingredients can be administered to a patient every 5 days. In certain embodiments, an effective dose of a composition or combination comprising the active ingredients can be administered to a patient every 6 days. In certain embodiments, an effective dose of a composition or combination comprising the active ingredients can be administered to a patient every 7 days. In certain embodiments, an effective dose of a composition or combination comprising the active ingredients can be administered to a patient every 8 days. In certain embodiments, an effective dose of a composition or combination comprising the active ingredients can be administered to a patient every 9 days. In certain embodiments, an effective dose of a composition or combination comprising the active ingredients can be administered to a patient every 10 days. In certain embodiments, an effective dose of a composition or combination comprising the active ingredients can be administered to a patient every 2 weeks. In certain embodiments, an effective dose of a composition or combination comprising the active ingredients can be administered to a patient every 3 weeks. In certain embodiments, an effective dose of a composition or combination comprising the active ingredients can be administered to a patient monthly. In certain embodiments, an effective dose of a composition or combination comprising the active ingredients can be administered to a patient every 1-14 days. In certain embodiments, an effective dose of a composition or combination comprising the active ingredients can be administered to a patient every 2-12 days. In certain embodiments, an effective dose of a composition or combination comprising the active ingredients can be administered to a patient every 3-10 days. In certain embodiments, an effective dose of a composition or combination comprising the active ingredients can be administered to a patient every 5-10 days. In certain embodiments, an effective dose of a composition or combination comprising the active ingredients can be administered to a patient every 5-14 days.
[0137] For systemic administration, subjects can be administered a therapeutic amount of a composition or combination described herein, such as, e.g. 0.1 mg / kg, 0.5 mg / kg, 1.0 mg / kg, 2.0434928-7411-2416 2Attorney Docket No: 105619-000001WOPTmg / kg, 2.5 mg / kg, 5 mg / kg, 10 mg / kg, 15 mg / kg, 20 mg / kg, 25 mg / kg, 30 mg / kg, 40 mg / kg, 50 mg / kg, or more.
[0138] In some embodiments, after an initial treatment regimen, the treatments can be administered on a less frequent basis. For example, after treatment biweekly for three months, treatment can be repeated once per month, for six months or a year or longer. Treatment according to the methods described herein can reduce levels of a marker or symptom of a condition, e.g., by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80 % or at least 90% or more.
[0139] The dosage of a composition as described herein can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment. With respect to duration and frequency of treatment, it is typical for skilled clinicians to monitor subjects in order to determine when the treatment is providing therapeutic benefit, and to determine whether to increase or decrease dosage, increase or decrease administration frequency, discontinue treatment, resume treatment, or make other alterations to the treatment regimen. The dosing schedule can vary from once a week to daily depending on a number of clinical factors, such as the subject's sensitivity to one or more active ingredients. The desired dose or amount of activation can be administered at one time or divided into subdoses, e.g., 2-4 subdoses and administered over a period of time, e.g., at appropriate intervals throughout the day or other appropriate schedule. In some embodiments, administration can be chronic, e.g., one or more doses and / or treatments daily over a period of weeks or months. Examples of dosing and / or treatment schedules are administration daily, twice daily, three times daily or four or more times daily over a period of 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months, or more. A composition or combination described herein can be administered over a period of time, such as over a 5 minute, 10 minute, 15 minute, 20 minute, or 25 minute period.
[0140] The dosage ranges for the administration of a composition or combination described herein, according to the methods described herein depend upon, for example, the form of the composition or combination described herein, its potency, and the extent to which symptoms, markers, or indicators of a condition described herein are desired to be reduced, for example the percentage reduction desired for inflammatory markers or the extent to which, for example, muscle mass is desired to be induced. The dosage should not be so large as to cause adverse side effects. Generally, the dosage will vary with the age, condition, and sex of the patient and can be determined by one of skill in the art. The dosage can also be adjusted by the individual physician in the event of any complication.
[0141] The efficacy of a composition or combination described herein in, e.g. the treatment of a condition described herein, or to induce a response as described herein (e.g. increase in healthy B cells and HSP levels) can be determined by the skilled clinician. However, a treatment is considered “effective treatment," as the term is used herein, if one or more of the signs or symptoms of a444928-7411-2416 2Attorney Docket No: 105619-000001WOPTcondition described herein are altered in a beneficial manner, other clinically accepted symptoms are improved, or even ameliorated, or a desired response is induced e.g., by at least 10% following treatment according to the methods described herein. Efficacy can be assessed, for example, by measuring a marker, indicator, symptom, and / or the incidence of a condition treated according to the methods described herein or any other measurable parameter appropriate, e.g. as described herein. Efficacy can also be measured by a failure of an individual to worsen as assessed by hospitalization, or need for medical interventions (i.e., progression of the disease is halted). Methods of measuring these indicators are known to those of skill in the art and / or are described herein. Treatment includes any treatment of a disease in an individual or an animal (some non-limiting examples include a human or an animal) and includes: (1) inhibiting the disease, e.g., preventing a worsening of symptoms (e.g. pain or inflammation); or (2) relieving the severity of the disease, e.g., causing regression of symptoms. An effective amount for the treatment of a disease means that amount which, when administered to a subject in need thereof, is sufficient to result in effective treatment as that term is defined herein, for that disease. Efficacy of an agent can be determined by assessing physical indicators of a condition or desired response, (e.g. as described elsewhere herein). It is well within the ability of one skilled in the art to monitor efficacy of administration and / or treatment by measuring any one of such parameters, or any combination of parameters. Efficacy can be assessed in animal models of a condition described herein, for example treatment of geriatric animals. When using an experimental animal model, efficacy of treatment is evidenced when a statistically significant change in a marker is observed.
[0142] In vitro and animal model assays are provided herein which allow the assessment of a given dose of a composition or combination described herein.
[0143] In one respect, the present invention relates to the herein described compositions, methods, and respective component(s) thereof, as essential to the technology, yet open to the inclusion of unspecified elements, essential or not ("comprising). In some embodiments of any of the aspects, other elements to be included in the description of the composition, method or respective component thereof are limited to those that do not materially affect the basic and novel characteristic(s) of the technology (e.g., the composition, method, or respective component thereof “consists essentially of’ the elements described herein). This applies equally to steps within a described method as well as compositions and components therein. In other embodiments of any of the aspects, the compositions, methods, and respective components thereof, described herein are intended to be exclusive of any element not deemed an essential element to the component, composition or method (e.g., the composition, method, or respective component thereof “consists of’ the elements described herein). This applies equally to steps within a described method as well as compositions and components therein.454928-7411-2416 2Attorney Docket No: 105619-000001WOPT
[0144] For convenience, the meaning of some terms and phrases used in the specification, examples, and appended claims, are provided below. Unless stated otherwise, or implicit from context, the following terms and phrases include the meanings provided below. The definitions are provided to aid in describing particular embodiments, and are not intended to limit the claimed invention, because the scope of the invention is limited only by the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. If there is an apparent discrepancy between the usage of a term in the art and its definition provided herein, the definition provided within the specification shall prevail.
[0145] The terms “decrease”, “reduced”, “reduction”, or “inhibit” are all used herein to mean a decrease by a statistically significant amount. In some embodiments, “reduce,” “reduction" or “decrease" or “inhibit” typically means a decrease by at least 10% as compared to a reference level (e.g. the absence of a given treatment or agent) and can include, for example, a decrease by at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99% , or more. As used herein, “reduction” or “inhibition” does not encompass a complete inhibition or reduction as compared to a reference level. “Complete inhibition” is a 100% inhibition as compared to a reference level. A decrease can be preferably down to a level accepted as within the range of normal for an individual without a given disorder.
[0146] The terms “increased”, “increase”, “enhance”, or “activate” are all used herein to mean an increase by a statistically significant amount. In some embodiments, the terms “increased”, “increase”, “enhance”, or “activate” can mean an increase of at least 10% as compared to a reference level, for example an increase of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% or up to and including a 100% increase or any increase between 10-100% as compared to a reference level, or at least about a 2-fold, or at least about a 3 -fold, or at least about a 4-fold, or at least about a 5-fold or at least about a 10-fold increase, or any increase between 2-fold and 10-fold or greater as compared to a reference level. In the context of a marker or symptom, an “increase” is a statistically significant increase in such level.
[0147] As used herein, a "subject" means a human or animal. Usually, the animal is a vertebrate such as a primate, rodent, domestic animal or game animal. Primates include chimpanzees, cynomolgus monkeys, spider monkeys, and macaques, e.g., Rhesus. Rodents include mice, rats, woodchucks, ferrets, rabbits and hamsters. Domestic and game animals include cows, horses, pigs, deer, bison, buffalo, feline species, e.g., domestic cat, canine species, e.g., dog, fox, wolf, avian464928-7411-2416 2Attorney Docket No: 105619-000001WOPTspecies, e.g., chicken, emu, ostrich, and fish, e.g., trout, catfish and salmon. In some embodiments, the subject is a mammal, e.g., a primate, e.g., a human. The terms, “individual,” “patient” and “subject” are used interchangeably herein.
[0148] Preferably, the subject is a mammal. The mammal can be a human, non-human primate, mouse, rat, dog, cat, horse, or cow, but is not limited to these examples. Mammals other than humans can be advantageously used as subjects that represent animal models of, e.g., geriatric syndrome. A subject can be male or female.
[0149] A subject can be one who has been previously diagnosed with or identified as suffering from or having a condition in need of treatment (e.g. a geriatric syndrome) or one or more complications related to such a condition, and optionally, have already undergone treatment for the condition or the one or more complications related to the condition. Alternatively, a subject can also be one who has not been previously diagnosed as having the condition or one or more complications related to the condition. For example, a subject can be one who exhibits one or more risk factors for the condition or one or more complications related to the condition or a subject who does not exhibit risk factors.
[0150] A “subject in need” of treatment for a particular condition can be a subject having that condition, diagnosed as having that condition, or at risk of developing that condition.
[0151] As used herein, the terms "treat,” "treatment," "treating,” or “amelioration” refer to therapeutic treatments, wherein the object is to reverse, alleviate, ameliorate, inhibit, slow down or stop the progression or severity of a condition associated with a disease or disorder, e.g. a geriatric syndrome. The term “treating" includes reducing or alleviating at least one adverse effect or symptom of a condition, disease or disorder associated with, e.g., a geriatric syndrome. Treatment is generally “effective" if one or more symptoms or clinical markers are reduced. Alternatively, treatment is “effective" if the progression of a disease is reduced or halted. That is, “treatment" includes not just the improvement of symptoms or markers, but also a cessation of, or at least slowing of, progress or worsening of symptoms compared to what would be expected in the absence of treatment. Beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptom(s), diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, remission (whether partial or total), and / or decreased mortality, whether detectable or undetectable. The term "treatment" of a disease also includes providing relief from the symptoms or side-effects of the disease (including palliative treatment).
[0152] In some embodiments of any of the aspects, described herein is a prophylactic method of treatment. As used herein “prophylactic” refers to the timing and intent of a treatment relative to a disease or symptom, that is, the treatment is administered prior to clinical detection or diagnosis of that particular disease or symptom in order to protect the patient from the disease or symptom.474928-7411-2416 2Attorney Docket No: 105619-000001WOPTProphylactic treatment can encompass a reduction in the severity or speed of onset of the disease or symptom or contribute to faster recovery from the disease or symptom. Accordingly, the methods described herein can be prophylactic relative to a decrease in muscle mass. In some embodiments of any of the methods described herein can be prophylactic relative to falling. In some embodiments of any of the methods described herein can be prophylactic relative to exhibiting difficulty in walking. In some embodiments of any of the methods described herein can be prophylactic relative to exhibiting 3 symptoms of geriatric frailty. In some embodiments of any of the methods described herein can be prophylactic relative to exhibiting 4 symptoms of geriatric frailty. In some embodiments of any of the methods described herein can be prophylactic relative to exhibiting 5 symptoms of geriatric frailty. In some embodiments of any of the aspects, prophylactic treatment is not prevention of all symptoms or signs of a disease.
[0153] In some embodiments of any of the methods described herein can be prophylactic relative to stage 4 kidney failure. In some embodiments of any of the methods described herein can be prophylactic relative to exhibiting a body condition score of 1 out of 5 or less. In some embodiments of any of the methods described herein can be prophylactic relative to exhibiting a body condition score of 1.5 out of 5 or less. In some embodiments of any of the methods described herein can be prophylactic relative to exhibiting a body condition score of less than 2 out of 5.
[0154] As used herein, the term “pharmaceutical composition” refers to the active agent in combination with a pharmaceutically acceptable carrier e.g. a carrier commonly used in the pharmaceutical industry. The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio. In some embodiments of any of the aspects, a pharmaceutically acceptable carrier can be a carrier other than water. In some embodiments of any of the aspects, a pharmaceutically acceptable carrier can be a cream, emulsion, gel, liposome, nanoparticle, and / or ointment. In some embodiments of any of the aspects, a pharmaceutically acceptable carrier can be an artificial or engineered carrier, e.g., a carrier that the active ingredient would not be found to occur in in nature.
[0155] As used herein, the term "administering," refers to the placement of a compound as disclosed herein into a subject by a method or route which results in at least partial delivery of the agent at a desired site. Pharmaceutical compositions comprising the compounds disclosed herein can be administered by any appropriate route which results in an effective treatment in the subject. In some embodiments, administration comprises physical human activity, e.g., an injection, act of ingestion, an act of application, and / or manipulation of a delivery device or machine. Such activity can be performed, e.g., by a medical professional and / or the subject being treated.484928-7411-2416 2Attorney Docket No: 105619-000001WOPT
[0156] The term “statistically significant" or “significantly" refers to statistical significance and generally means a two standard deviation (2SD) or greater difference.
[0157] Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term “about.” The term “about” when used in connection with percentages can mean ±1%.
[0158] As used herein, the term “comprising” means that other elements can also be present in addition to the defined elements presented. The use of “comprising” indicates inclusion rather than limitation.
[0159] The term "consisting of refers to compositions, methods, and respective components thereof as described herein, which are exclusive of any element not recited in that description of the embodiment.
[0160] As used herein the term "consisting essentially of refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment of the invention.
[0161] The singular terms "a," "an," and "the" include plural referents unless context clearly indicates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of this disclosure, suitable methods and materials are described below. The abbreviation, "e.g." is derived from the Latin exempli gratia, and is used herein to indicate a non-limiting example. Thus, the abbreviation "e.g." is synonymous with the term "for example."
[0162] Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member can be referred to and claimed individually or in any combination with other members of the group or other elements found herein. One or more members of a group can be included in, or deleted from, a group for reasons of convenience and / or patentability. When any such inclusion or deletion occurs, the specification is herein deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.
[0163] Unless otherwise defined herein, scientific and technical terms used in connection with the present application shall have the meanings that are commonly understood by those of ordinary skill in the art to which this disclosure belongs. It should be understood that this invention is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such can vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which is defined solely by the claims. Definitions of common terms in biological sciences can be found in The Merck Manual of Diagnosis and Therapy, 20th Edition, published by Merck Sharp & Dohme Corp., 2018 (ISBN 0911910190, 978-494928-7411-2416 2Attorney Docket No: 105619-000001WOPT0911910421); Bruce Alberts et al., Molecular Biology of the Cell, published by W.W. Norton & Company, 2022 (ISBN 0393884821, 978-0393884821); John M. Lackie eat al. (eds.), The Dictionary of Cell and Molecular Biology, 5thEdition, published by Academic Press, 2013 (ISBN 0123849314, 978-0123849311); Nalini Chandar et al., Lippincott Illustrated Reviews: Cell and Molecular Biology, 3rdEdition, published by LWW, 2023 (ISBN 1975180895, 978-1975180898); Teresa Atwood et al., Oxford Dictionary of Biochemistry and Molecular Biology, 2ndEdition, published by Oxford University Press, 2006; Robert S. Porter et al. (eds.), The Encyclopedia of Molecular Cell Biology and Molecular Medicine, published by Blackwell Science Ltd., 1999-2012 (ISBN 9783527600908); Johnathan Law et al., (eds.), A Dictionary of Chemistry, 8thEdition, published by Oxford University Press, 2020 (ISBN 9780198841227, 9780191876783); Robert C. King et al. (eds.), A Dictionary of Genetics, 8thEdition, published by Oxford University Press, 2013 (ISBN 9780199766444, 9780199376865); Richard Cammack et al. (eds.), Oxford Dictionary of Biochemistry and Molecular Biology, 2ndEdition, published by Oxford University Press, 2006 (ISBN 9780198529170, 9780191727641); John Lackie et al. (eds.), A Dictionary of Biomedicine, 2ndEdition, published by Oxford University Press, 2019 (ISBN 9780191829116); Lodish et al., Molecular Cell Biology, 8thEdition, published by W.H. Freeman, 2016 (ISBN 1464183392, 978-1464183393); Abul K. Abbas et al., Cellular and Molecular Immunology, 10thEdition, published by Elsevier, 2021 (ISBN 0323757480, 978-0323757485); Kenneth M. Murphy et al., Janeway's Immunobiology, 10thEdition, published by W. W. Norton & Company, 2022 (ISBN 0393884899, 978-0393884890); Lewin's Genes XI, published by Jones & Bartlett Publishers, 2014 (ISBN-1449659055); Michael Richard Green and Joseph Sambrook, Molecular Cloning: A Laboratory Manual, 4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., USA (2012) (ISBN 1936113414); Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (2012) (ISBN 0444569464); Laboratory Methods in Enzymology: DNA, Jon Lorsch (ed.) Elsevier, 2013 (ISBN 0124199542); Frederick M. Ausubel (ed.), Current Protocols in Molecular Biology (CPMB), John Wiley and Sons, 1987-2010 (ISBN 047150338X, 9780471503385); Current Protocols in Protein Science (CPPS), John E. Coligan (ed.), John Wiley and Sons, Inc., 2005; and Current Protocols in Immunology (CPI) (John E. Coligan, ADA M Kruisbeek, David H Margulies, Ethan M Shevach, Warren Strobe, (eds.) John Wiley and Sons, Inc., 2003 (ISBN 0471142735, 9780471142737), the contents of which are all incorporated by reference herein in their entireties.
[0164] In all embodiments where a sample is obtained or has been obtained or provided, the sample can be sample taken, obtained, or provided via minimally invasive methods and / or involves only a minor intervention. In some embodiments of any of the aspects, a sample is taken, obtained, or provided by one or more of a blood draw or prick, an epidermal or mucus membrane swab, buccal sampling, saliva sample, a epidermal skin sampling technique, and / or collection of a secreted or expelled bodily fluid (e.g., mucus, urine, sweat, etc.), fecal sampling, semen / seminal fluid sampling,504928-7411-2416 2Attorney Docket No: 105619-000001WOPTor clippings (e.g., of hair or nails). In some embodiments of any of the aspects, the sample comprises, consists of, or consists essentially of blood (or any fraction or component thereof), serum, urine, mucus, epithelial cells, saliva, buccal cells, a secreted or expelled bodily fluid, and / or hair or nail clippings.
[0165] Other terms are defined herein within the description of the various aspects of the invention.
[0166] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0167] All patents and other publications; including literature references, issued patents, published patent applications, and co-pending patent applications; cited throughout this application are expressly incorporated herein by reference for the purpose of describing and disclosing, for example, the methodologies described in such publications that might be used in connection with the technology described herein. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents.
[0168] The description of embodiments of the disclosure is not intended to be exhaustive or to limit the disclosure to the precise form disclosed. While specific embodiments of, and examples for, the disclosure are described herein for illustrative purposes, various equivalent modifications are possible within the scope of the disclosure, as those skilled in the relevant art will recognize. For example, while method steps or functions are presented in a given order, alternative embodiments may perform functions in a different order, or functions may be performed substantially concurrently. The teachings of the disclosure provided herein can be applied to other procedures or methods as appropriate. The various embodiments described herein can be combined to provide further embodiments. Aspects of the disclosure can be modified, if necessary, to employ the compositions, functions and concepts of the above references and application to provide yet further embodiments of the disclosure. These and other changes can be made to the disclosure in light of the detailed description. All such modifications are intended to be included within the scope of the appended claims.
[0169] Specific elements of any of the foregoing embodiments can be combined or substituted for elements in other embodiments. Furthermore, while advantages associated with certain embodiments of the disclosure have been described in the context of these embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the disclosure.514928-7411-2416 2Attorney Docket No: 105619-000001WOPT
[0170] The technology described herein is further illustrated by the following examples which in no way should be construed as being further limiting.EXAMPLESExample 1
[0171] Age-related diseases (kidney failure, arthritis, sarcopenia) ultimately affect the companion cats of 74M Americans. There are currently no therapeutics for feline aging.
[0172] We have conducted state -supervised clinical trials and present herein data from sarcopenic elderly cats treated with PURR-0001.
[0173] PURR-0001
[0174] Gastro-resistant capsules were formulated, comprising:Rapamycin (0.5 mg per capsule)Mirtazapine (1.8 mg per capsule)Acarbose (10 mg per capsule)Glycine (200 mg per capsule)N-acetyl-L-cysteine (200 mg per capsule)The capsule was administered orally weekly to elderly sarcopenic cats weighing 3.5 kg or less.
[0175] Clinical inclusion and exclusion criteria
[0176] The elderly sarcopenic cats included in the PURR-001 trialAge: Cats >10 years, to target a geriatric population prone to sarcopenia.Body Condition: Underweight (BCS at or below 2 of 5) with evidence of lean mass loss.Muscle Condition: Mild to moderate muscle wasting based on palpation of epaxial, temporal, and scapular musculature.Stable Health Status: No severe acute or chronic illness; no cancer or end-stage disease (e.g., stage 4 renal failure).Mobility: Ambulatory with measurable physical activity; severe arthritis or neurologic deficits excluded.Laboratory Screening: Normal or controlled renal, hepatic, and thyroid function to minimize confounding metabolic effects.
[0177] Lab methods
[0178] Sample Preparation and RNA Extraction. Peripheral blood mononuclear cells (PBMCs) were isolated from domestic cats treated with placebo or therapeutics. Total RNA was extracted using TRIzol protocols. RNA integrity and quantity were assessed using EzDrop™ 1000.
[0179] Library Preparation and Sequencing. RNA libraries were prepared using the Oxford Nanopore Technologies (ONT) SQK-RNA004™ direct RNA sequencing kit, following the native protocol. Libraries were sequenced on the ONT PromethlON™ P2 Solo, generating a minimum of 2 gigabases (Gb) of base called data per sample.524928-7411-2416 2Attorney Docket No: 105619-000001WOPT
[0180] Read Alignment and Quantification
[0181] Base called reads were aligned to the Felis catus reference genome felCat9 using minimap2 with RNA-seq-specific settings. Gene-level count matrices were generated using featureCounts from the Rsubread package 2.18.0 with default parameters.
[0182] Differential Expression Analysis. Raw count data were analyzed for differential gene expression using DESeq2 (1.44.0) in R. DESeq2 was run with default parameters, including automatic normalization and dispersion estimation. Statistical significance was determined using the Benjamini-Hochberg procedure to control the false discovery rate (FDR), with genes considered differentially expressed at an adjusted p-value (FDR) < 0.05
[0183] RESULTS
[0184] Numbers of B-cells and T-cells decrease during aging. In particular, aging decreases CD19 B cell numbers. De Mol et al. Font. Immunol 12:733566 (2021). Additionally, the frequency of CD69+ CD4+ T cells increases with aging. Shen et al. Front Immunol. 15:1465124 (2024). The foregoing references are incorporated by reference herein in their entireties.
[0185] Cats treated with PURR-0001 had increased levels of CD 19+ B cells, and increased numbers of healthy B cells, e.g., those B cells with lower levels of CD69. CD69 is known to be a marker of immune cell activation and thus the PURR-0001 treated cats have less hyper-activated B cells. Fig. 1A. The PURR-0001 cats have reduced CD69 and other markers of chronic inflammation. Figs. 1A-1B.
[0186] HSP (heat shock protein) gene upregulation is associated with longer lifespan due to better proteostasis. Murshid et al. Int. J. Hyperthemia 29:442-447 (2013). The PURR-0001 treated cats had increased HSP expression. Fig. IB. The PURR-0001 cats had increased hermetic expression of protective HSPs. The foregoing references are incorporated by reference herein in their entireties.
[0187] Veterinarian observation of the treated cats indicated weight gain and behavioral indications of improved health with no adverse effects.Example 2
[0188] The expression of a panel of genes in response to PURR-001 and its individual components were examined. PURR-001 can amplify some responses, as well as providing unique responses that distinguish it from the effect of individual components (Figs. 2A-2D). PRRX1 (downregulated) and TGM2 (upregulated) display synergistic responses in omic screens from feline cell lines to PURR-001.
[0189] Sarcopenic cats given PURR-001 gained more weight than sarcopenic cats given placebo (microcrystalline cellulose) at the 6 weeks timepoint (Fig. 3). On average, placebo-treated cats increased in weight by 3.45%, while PURR-001 -treated cats increased in weight 8.94%. To determine if the weight gain reflected an increase in muscle weight, ultrasound profiling of epaxial muscle group534928-7411-2416 2Attorney Docket No: 105619-000001WOPTthickness was performed (Figs. 4A-4B). PURR-001 treatment increases epaxial muscle thickness in sarcopenic elderly cats. In this particular case, the cat increased in weight considerably (several hundred grams) and also increased its epaxial muscle thickness by 16.45% (from an average readout of 15.2 mm to 17.7 mm).
[0190] The safety and tolerability of PURR-001 oral capsules was tested in sarcopenic elderly cats over the course of 12 weeks. No significant changes were observed in renal (creatinine (Fig. 5B) or hepatic (albumin (Fig. 5 A) in dozens of cats given PURR-001 or placebo.544928-7411-2416 2
Claims
Attorney Docket No: 105619-000001W0PTWhat is claimed herein is:
1. A composition or combination comprising at least two of:a) at least one mTOR inhibitor;b) mirtazapine;c) at least one of acarbose and metformin;d) glycine; ande) N-acetyl-L-cysteine.
2. The composition or combination of any one of the preceding claims, comprising at least two of:a) at least one mTOR inhibitor;b) mirtazapine; andc) at least one of acarbose and metformin.
3. The composition or combination of any one of the preceding claims, comprising at least three of:a) at least one mTOR inhibitor;b) mirtazapine;c) at least one of acarbose and metformin;d) glycine; ande) N-acetyl-L-cysteine.
4. The composition or combination of any one of the preceding claims, comprising each of: a) at least one mTOR inhibitor;b) mirtazapine; andc) at least one of acarbose and metformin.
5. The composition or combination of any one of the preceding claims, comprising at least four of:a) at least one mTOR inhibitor;b) mirtazapine;c) at least one of acarbose and metformin;d) glycine; ande) N-acetyl-L-cysteine.
6. The composition or combination of any one of the preceding claims, comprising each of: a) at least one mTOR inhibitor;b) mirtazapine;c) at least one of acarbose and metformin;d) glycine; and554928-7411-2416 2Attorney Docket No: 105619-000001WOPTe) N-acetyl-L-cysteine.
7. The composition or combination of any one of the preceding claims, wherein the at least one mTOR inhibitor is rapamycin.
8. The composition or combination of any one of the preceding claims, comprising acarbose.
9. The composition or combination of any one of the preceding claims, comprising metformin.
10. The composition or combination of any one of the preceding claims, comprising metformin and acarbose.
11. The composition or combination of any one of the preceding claims, wherein the at least one mTOR inhibitor is at a dosage of 0.1 mg to 1 mg.
12. The composition or combination of any one of the preceding claims, wherein the rapamycin is at a dosage of 0.1 mg to 1 mg.
13. The composition or combination of any one of the preceding claims, wherein the mirtazapine is at a dosage of 1 mg to 3 mg.
14. The composition or combination of any one of the preceding claims, wherein the acarbose is at a dosage of 5 mg to 20 mg.
15. The composition or combination of any one of the preceding claims, wherein the metformin is at a dosage of 1 mg to 20 mg.
16. The composition or combination of any one of the preceding claims, wherein the glycine is at a dosage of 100 mg to 400 mg.
17. The composition or combination of any one of the preceding claims, wherein the N-acetyl-L- cysteine is at a dosage of 100 mg to 400 mg.
18. The composition or combination of any one of the preceding claims, formulated as one or more oral formulations.
19. The composition or combination of any one of the preceding claims, formulated as an oral formulation.
20. The composition or combination of any one of the preceding claims, wherein the oral formulation is a pill, tablet, capsule, chewable formulation, orally disintegrating formulation, powder, pellet, liquid, syrup, solution, or drop.
21. The composition or combination of any one of the preceding claims, wherein the oral formulation is a pill, tablet, capsule, chewable formulation, and / or an orally disintegrating formulation.
22. The composition or combination of any one of the preceding claims, wherein the oral formulation is a gastro-resistant pill, gastro-resistant tablet, or gastro-resistant capsule.
23. A method of treating a geriatric syndrome in a subject in need thereof, the method comprising administering a composition or combination of any one of the preceding claims.564928-7411-2416 2Attorney Docket No: 105619-000001WOPT24. The method of any one of the preceding claims, wherein the geriatric syndrome is selected from the group consisting of:sarcopenia, chronic kidney disease, neurodegenerative disease, musculoskeletal disorder, and myelodysplastic syndrome.
25. The method of any one of the preceding claims, wherein the geriatric syndrome is sarcopenia.
26. A method of increasing longevity in a subject, the method comprising administering a composition or combination of any one of the preceding claims.
27. A method of reducing geriatric frailty or reducing the rate of increase of geriatric frailty in a subject, the method comprising administering a composition or combination of any one of the preceding claims.
28. The method of any one of claims 26-27, wherein the method is not a method for treatment of the human or animal body by surgery or therapy practiced on the human or animal body.
29. The method of any one of the preceding claims, wherein the subject is a feline.
30. The method of any one of the preceding claims, wherein the subject is geriatric.
31. The method of any one of the preceding claims, wherein the subject is a feline of at least 10 years of age.
32. The method of any one of the preceding claims, wherein the composition or combination is administered every 3-10 days.
33. The method of any one of the preceding claims, wherein the composition or combination is administered weekly.574928-7411-2416 2
